

Table 1.4
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	All Races								
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	442.4	480.3	418.3	158.3	189.5	135.7	67.4	66.4	68.5
Oral Cavity & Pharynx:	11.4	17.2	6.4	2.5	3.9	1.3	66.2	65.6	67.7
Lip	0.6	1.0	0.3	0.0	0.0	0.0	92.0	91.8	90.5
Tongue	3.5	5.3	1.9	0.7	1.0	0.4	67.1	67.5	66.2
Salivary gland	1.3	1.7	1.0	0.3	0.4	0.1	72.3	65.5	81.7
Floor of mouth	0.5	0.7	0.3	0.0	0.0	0.0	51.1	49.0	55.8
Gum & other oral cavity	1.5	1.9	1.3	0.4	0.5	0.3	59.8	57.0	63.3
Nasopharynx	0.6	0.9	0.3	0.2	0.3	0.1	61.3	59.1	66.6
Tonsil	2.0	3.5	0.7	0.2	0.4	0.1	75.1	75.4	73.1
Oropharynx	0.5	0.8	0.2	0.3	0.4	0.1	49.0	51.1	41.0
Hypopharynx	0.6	1.0	0.2	0.1	0.2	0.0	36.1	36.1	36.2
Other oral cavity & pharynx	0.3	0.5	0.1	0.4	0.7	0.2	47.9	50.4	38.2
Digestive System:	81.0	98.5	66.4	40.9	52.4	31.4	43.6	41.3	46.6
Esophagus	4.3	7.3	1.7	3.9	7.0	1.4	19.9	19.3	22.6
Stomach	7.3	9.9	5.3	3.1	4.1	2.2	32.0	28.9	36.7
Small intestine	2.4	2.8	2.1	0.4	0.5	0.3	68.3	68.1	68.5
Colon & Rectum:	38.2	43.7	33.6	13.9	16.6	11.8	64.6	64.0	65.1
Colon	26.8	29.5	24.6	-	-	-	63.4	63.2	63.6
Rectum	11.4	14.3	9.1	-	-	-	67.1	65.6	69.1
Anus, anal canal & anorectum	1.9	1.6	2.2	0.3	0.2	0.3	68.7	63.7	71.5
Liver & intrahepatic bile duct	9.0	13.8	4.8	6.6	9.6	4.0	19.6	19.3	20.5
Gallbladder	1.2	0.9	1.5	0.6	0.4	0.7	19.2	20.6	18.6
Other biliary	1.9	2.3	1.5	0.4	0.5	0.4	18.7	19.7	17.5
Pancreas	13.1	14.9	11.6	11.0	12.7	9.6	10.0	10.0	10.0
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	55.2	53.6	56.6
Peritoneum, omentum & mesentery	0.5	0.1	0.8	0.3	0.1	0.4	32.4	36.5	32.2
Other digestive system	0.8	0.9	0.7	0.4	0.4	0.3	7.3	6.2	8.4
Respiratory System:	57.9	67.9	50.3	41.5	51.5	33.8	23.4	21.7	25.5
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.1	0.2	0.1	58.1	58.3	57.6
Larynx	2.9	5.0	1.1	1.0	1.7	0.4	60.6	61.3	57.6
Lung & bronchus	54.2	61.7	48.6	40.2	49.3	33.2	20.5	17.1	24.2
Pleura ^d	0.0	0.0	0.0	0.1	0.1	0.0	24.3	17.3	34.2
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	54.9	54.0	57.4
Bones & joints	1.0	1.1	0.8	0.5	0.6	0.4	66.0	63.8	68.7
Soft tissue (including heart)	3.5	4.2	2.9	1.3	1.5	1.2	64.7	64.4	65.1
Skin (excl. basal & squamous):	24.7	32.2	19.3	3.4	5.3	1.9	92.0	90.3	94.4
Melanoma of the skin	22.7	29.3	17.8	2.4	3.5	1.5	92.7	91.1	94.8
Other non-epithelial skin	2.1	2.9	1.5	1.0	1.7	0.5	83.7	80.9	88.0
Breast	68.9	1.2	128.5	11.3	0.3	20.3	90.0	83.6	90.0
Breast (<i>in situ</i>)	17.4	0.1	33.0	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.4 - continued
 Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
 By Primary Cancer Site, Sex and Time Period

All Races

Site	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.2	-	51.3	8.2	-	15.1	70.0	-	70.0
Cervix uteri	3.8	-	7.4	1.2	-	2.3	66.1	-	66.1
Corpus uteri	14.3	-	27.0	1.2	-	2.3	82.7	-	82.7
Uterus, NOS	0.5	-	0.9	1.4	-	2.6	28.5	-	28.5
Ovary ^d	6.0	-	11.2	3.8	-	6.9	48.6	-	48.6
Vagina	0.4	-	0.7	0.1	-	0.2	48.5	-	48.5
Vulva	1.4	-	2.6	0.3	-	0.5	70.4	-	70.4
Other female genital system	0.9	-	1.7	0.2	-	0.4	50.8	-	50.8
Male Genital System:	53.7	116.9	-	8.1	19.6	-	97.5	97.5	-
Prostate	50.2	109.8	-	7.8	19.1	-	97.8	97.8	-
Testis	3.0	5.9	-	0.1	0.3	-	95.0	95.0	-
Penis	0.4	0.9	-	0.1	0.2	-	65.4	65.4	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	82.8	82.8	-
Urinary System:	37.2	58.7	20.3	8.3	13.3	4.6	75.5	76.2	73.9
Urinary bladder	20.0	34.9	8.6	4.4	7.5	2.1	76.9	78.3	72.4
Kidney & renal pelvis	16.3	22.4	11.1	3.7	5.4	2.3	75.2	74.5	76.3
Ureter	0.5	0.8	0.4	0.1	0.2	0.1	47.4	48.9	45.3
Other urinary system	0.4	0.7	0.2	0.1	0.2	0.1	48.2	51.5	41.7
Eye & Orbit	0.9	1.0	0.8	0.1	0.1	0.1	83.2	83.6	82.6
Brain & Nervous System: ^e	6.4	7.5	5.4	4.4	5.4	3.6	32.6	31.3	34.2
Brain	6.0	7.1	5.0	-	-	-	29.4	28.5	30.5
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	80.1	78.0	82.1
Endocrine System:	16.5	9.0	23.8	0.8	0.8	0.8	96.6	92.8	97.9
Thyroid	15.7	8.1	23.1	0.5	0.5	0.5	98.3	95.9	98.9
Other endocrine & thymus	0.8	0.9	0.7	0.3	0.3	0.3	65.3	66.0	64.5
Lymphoma:	22.2	26.8	18.5	5.8	7.5	4.5	74.6	73.5	76.0
Hodgkin lymphoma	2.6	2.9	2.3	0.3	0.4	0.2	87.4	86.5	88.6
Non-Hodgkin lymphoma	19.6	23.8	16.2	5.5	7.1	4.2	72.7	71.5	74.2
Myeloma	7.0	8.8	5.7	3.3	4.1	2.6	53.9	53.7	54.1
Leukemia:	14.1	18.1	11.0	6.4	8.6	4.8	63.7	64.6	62.4
Lymphocytic:	7.1	9.4	5.3	1.7	2.4	1.2	81.3	81.6	80.9
Acute lymphocytic	1.7	2.0	1.5	0.4	0.5	0.4	68.8	68.4	69.2
Chronic lymphocytic	5.0	6.8	3.5	1.2	1.7	0.8	86.1	85.9	86.3
Other lymphocytic	0.4	0.6	0.2	0.1	0.2	0.1	82.4	85.3	73.2
Myeloid & Monocytic:	6.5	8.1	5.3	3.4	4.4	2.6	42.7	42.6	42.9
Acute myeloid	4.3	5.2	3.6	2.8	3.6	2.2	28.7	27.7	29.9
Chronic myeloid	1.9	2.5	1.5	0.3	0.4	0.2	70.4	69.5	71.6
Acute monocytic	0.2	0.2	0.2	0.0	0.0	0.0	23.6	21.7	25.7
Other myeloid & monocytic	0.1	0.2	0.1	0.2	0.4	0.2	38.7	40.7	36.0
Other leukemia:	0.5	0.6	0.4	1.3	1.8	1.0	34.1	35.4	32.5
Other acute leukemia	0.2	0.3	0.2	0.4	0.6	0.3	25.9	27.9	23.6
Aleukemic, subleukemic & NOS	0.3	0.3	0.2	0.9	1.2	0.7	40.4	41.6	39.1
Kaposi Sarcoma ^f	0.5	0.9	0.1	-	-	-	74.4	73.8	79.8
Mesothelioma ^f	0.9	1.6	0.4	-	-	-	10.1	7.7	17.1
Ill-defined & unspecified	7.5	8.7	6.5	11.6	14.6	9.4	18.6	22.0	15.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	452.1	485.5	432.0	159.0	189.6	136.4	67.8	66.5	69.1
Oral Cavity & Pharynx:	12.0	18.1	6.6	2.5	3.9	1.4	67.6	67.3	68.3
Lip	0.7	1.1	0.4	0.0	0.0	0.0	92.0	91.9	90.1
Tongue	3.9	5.9	2.1	0.7	1.0	0.4	68.6	69.0	67.3
Salivary gland	1.3	1.8	1.0	0.3	0.4	0.1	70.5	63.6	80.9
Floor of mouth	0.5	0.7	0.3	0.0	0.0	0.0	52.3	50.2	56.9
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	59.8	57.2	62.9
Nasopharynx	0.4	0.5	0.2	0.1	0.2	0.1	58.1	55.8	63.8
Tonsil	2.3	3.9	0.8	0.3	0.4	0.1	76.3	76.6	74.7
Oropharynx	0.5	0.8	0.2	0.3	0.4	0.1	52.1	54.7	41.7
Hypopharynx	0.5	0.9	0.2	0.1	0.2	0.0	39.3	39.3	39.1
Other oral cavity & pharynx	0.3	0.5	0.1	0.4	0.7	0.2	51.1	54.1	38.3
Digestive System:	79.1	95.8	65.0	40.0	51.1	30.5	43.8	41.4	46.8
Esophagus	4.5	7.8	1.8	4.2	7.4	1.4	20.6	20.1	22.8
Stomach	6.5	8.9	4.6	2.7	3.6	1.9	30.8	27.7	35.9
Small intestine	2.3	2.7	2.0	0.4	0.5	0.3	69.0	68.5	69.6
Colon & Rectum:	37.8	43.0	33.3	13.6	16.2	11.5	65.0	64.5	65.5
Colon	26.5	29.0	24.4	-	-	-	64.2	63.9	64.5
Rectum	11.2	13.9	8.9	-	-	-	66.7	65.6	68.2
Anus, anal canal & anorectum	2.1	1.6	2.5	0.3	0.2	0.3	69.7	64.9	72.2
Liver & intrahepatic bile duct	8.1	12.4	4.4	6.2	9.0	3.8	18.7	18.6	18.9
Gallbladder	1.1	0.8	1.4	0.5	0.4	0.7	19.4	20.7	18.7
Other biliary	1.8	2.3	1.5	0.4	0.5	0.4	18.1	19.6	16.2
Pancreas	13.1	15.0	11.6	10.9	12.7	9.4	9.8	9.9	9.8
Retroperitoneum	0.4	0.4	0.3	0.1	0.1	0.1	55.1	53.6	56.4
Peritoneum, omentum & mesentery	0.5	0.1	0.9	0.3	0.1	0.4	31.6	33.0	31.6
Other digestive system	0.8	0.9	0.7	0.3	0.4	0.3	6.8	6.0	7.6
Respiratory System:	59.9	68.5	53.3	42.3	51.5	35.1	23.5	21.8	25.4
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.1	0.2	0.1	58.4	59.3	57.0
Larynx	2.9	5.1	1.1	0.9	1.7	0.4	61.7	62.3	59.2
Lung & bronchus	56.0	62.2	51.5	41.0	49.4	34.5	20.6	17.2	24.2
Pleura ^d	0.0	0.0	0.0	0.1	0.1	0.0	23.2	19.8	29.7
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	54.7	53.5	57.8
Bones & joints	1.0	1.2	0.9	0.5	0.6	0.4	66.0	63.5	69.3
Soft tissue (including heart)	3.5	4.3	2.9	1.3	1.6	1.1	64.8	64.6	65.0
Skin (excl. basal & squamous):	29.4	37.7	23.2	3.9	6.0	2.2	91.4	89.5	94.0
Melanoma of the skin	27.2	34.6	21.7	2.8	4.1	1.7	92.2	90.4	94.5
Other non-epithelial skin	2.2	3.1	1.5	1.1	1.9	0.5	81.1	78.2	85.7
Breast	69.5	1.2	131.3	10.9	0.3	19.8	90.9	85.7	90.9
Breast (<i>in situ</i>)	17.0	0.1	32.8	-	-	-	100.0	99.9	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.5 - continued
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Whites								
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.5	-	52.4	8.1	-	14.9	71.3	-	71.3
Cervix uteri	3.7	-	7.2	1.1	-	2.2	67.5	-	67.5
Corpus uteri	14.5	-	27.6	1.2	-	2.1	84.9	-	84.9
Uterus, NOS	0.4	-	0.8	1.3	-	2.3	30.2	-	30.2
Ovary ^d	6.2	-	11.7	3.9	-	7.1	48.4	-	48.4
Vagina	0.4	-	0.7	0.1	-	0.2	48.3	-	48.3
Vulva	1.5	-	2.8	0.3	-	0.6	69.8	-	69.8
Other female genital system	0.9	-	1.7	0.2	-	0.4	49.8	-	49.8
Male Genital System:	51.4	110.5	-	7.6	18.4	-	97.4	97.4	-
Prostate	47.3	102.3	-	7.4	17.9	-	97.8	97.8	-
Testis	3.6	7.1	-	0.1	0.3	-	95.0	95.0	-
Penis	0.4	0.9	-	0.1	0.2	-	65.2	65.2	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	83.5	83.5	-
Urinary System:	39.8	62.7	21.4	8.7	13.9	4.7	75.8	76.4	74.4
Urinary bladder	22.0	38.2	9.4	4.6	8.0	2.2	77.3	78.5	73.5
Kidney & renal pelvis	16.8	23.0	11.4	3.8	5.6	2.4	75.1	74.4	76.2
Ureter	0.6	0.8	0.4	0.1	0.2	0.1	48.4	49.1	47.5
Other urinary system	0.4	0.7	0.2	0.1	0.2	0.1	47.6	50.7	40.6
Eye & Orbit	1.0	1.1	0.9	0.1	0.1	0.1	82.7	82.9	82.6
Brain & Nervous System: ^e	7.1	8.3	6.0	4.8	5.8	3.9	31.3	30.0	33.0
Brain	6.6	7.8	5.6	-	-	-	28.2	27.4	29.4
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	80.9	78.9	82.9
Endocrine System:	17.2	9.4	24.9	0.8	0.9	0.7	97.0	93.3	98.2
Thyroid	16.4	8.6	24.3	0.5	0.5	0.5	98.5	96.2	99.1
Other endocrine & thymus	0.8	0.8	0.7	0.3	0.3	0.3	64.7	65.5	63.8
Lymphoma:	23.4	28.0	19.5	6.0	7.8	4.7	74.9	73.8	76.4
Hodgkin lymphoma	2.8	3.1	2.5	0.3	0.4	0.2	87.5	86.6	88.6
Non-Hodgkin lymphoma	20.6	25.0	17.0	5.7	7.4	4.4	73.1	71.9	74.6
Myeloma	6.4	8.2	5.0	3.0	3.9	2.4	52.7	52.8	52.5
Leukemia:	15.0	19.2	11.6	6.7	8.9	5.0	64.0	64.4	63.3
Lymphocytic:	7.8	10.2	5.7	1.8	2.5	1.3	81.3	81.2	81.5
Acute lymphocytic	1.9	2.2	1.6	0.5	0.6	0.4	68.4	67.6	69.6
Chronic lymphocytic	5.4	7.3	3.9	1.2	1.8	0.8	85.9	85.4	86.7
Other lymphocytic	0.4	0.7	0.2	0.1	0.2	0.1	83.3	86.0	74.6
Myeloid & Monocytic:	6.8	8.4	5.5	3.5	4.6	2.7	41.9	41.5	42.5
Acute myeloid	4.4	5.4	3.7	2.9	3.7	2.2	28.3	27.2	29.6
Chronic myeloid	2.0	2.6	1.5	0.3	0.4	0.2	69.3	68.2	70.9
Acute monocytic	0.2	0.2	0.2	0.0	0.0	0.0	24.0	21.7	26.9
Other myeloid & monocytic	0.1	0.2	0.1	0.3	0.4	0.2	36.7	38.1	34.7
Other leukemia:	0.5	0.6	0.4	1.4	1.8	1.0	32.5	33.2	31.7
Other acute leukemia	0.2	0.3	0.2	0.5	0.6	0.4	25.3	27.2	23.2
Aleukemic, subleukemic & NOS	0.3	0.3	0.2	0.9	1.2	0.7	38.4	38.3	38.4
Kaposi Sarcoma ^f	0.4	0.7	0.1	-	-	-	77.5	75.8	86.9
Mesothelioma ^f	1.0	1.7	0.5	-	-	-	9.5	7.3	16.3
Ill-defined & unspecified	7.6	8.9	6.6	11.8	14.8	9.5	19.4	23.3	15.4

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Blacks								
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	440.4	515.1	390.7	181.7	227.3	153.4	62.5	64.4	60.6
Oral Cavity & Pharynx:	8.5	13.3	4.9	2.7	4.5	1.3	49.5	47.6	53.8
Lip	0.1	0.1	0.0	-	-	-	72.0	63.8	-
Tongue	1.9	3.2	1.0	0.5	0.8	0.3	46.4	47.1	44.6
Salivary gland	1.1	1.1	1.1	0.2	0.3	0.2	74.3	68.6	78.9
Floor of mouth	0.4	0.7	0.2	0.0	0.1	-	40.2	40.1	39.1
Gum & other oral cavity	1.2	1.5	1.0	0.3	0.5	0.2	53.7	48.7	58.9
Nasopharynx	0.7	1.0	0.3	0.2	0.4	0.1	52.1	53.8	48.9
Tonsil	1.6	2.9	0.6	0.2	0.4	0.1	58.9	59.5	56.0
Oropharynx	0.6	1.0	0.3	0.4	0.6	0.2	31.7	31.1	32.4
Hypopharynx	0.8	1.4	0.3	0.2	0.3	0.0	21.3	21.1	21.7
Other oral cavity & pharynx	0.2	0.4	0.1	0.6	1.1	0.2	30.8	29.0	35.4
Digestive System:	94.7	117.4	78.2	51.7	67.5	40.2	40.5	37.0	44.3
Esophagus	3.7	6.1	2.0	3.2	5.3	1.6	14.0	12.2	17.7
Stomach	10.1	13.8	7.6	5.3	7.8	3.6	31.9	26.1	39.4
Small intestine	3.8	4.4	3.4	0.6	0.8	0.6	65.8	66.6	65.0
Colon & Rectum:	43.6	51.3	38.2	18.5	23.2	15.2	58.8	56.8	60.6
Colon	32.0	36.5	28.8	-	-	-	57.0	56.2	57.7
Rectum	11.6	14.8	9.3	-	-	-	63.4	58.3	69.4
Anus, anal canal & anorectum	2.1	2.2	1.9	0.3	0.3	0.2	62.3	57.7	66.7
Liver & intrahepatic bile duct	10.7	17.7	5.4	8.4	13.2	4.8	17.1	15.9	20.5
Gallbladder	1.8	1.4	2.2	0.9	0.7	1.0	16.3	15.5	16.5
Other biliary	1.8	2.1	1.6	0.4	0.5	0.4	17.1	14.9	19.0
Pancreas	15.3	16.9	14.1	13.3	14.9	12.0	10.1	9.2	10.8
Retroperitoneum	0.4	0.3	0.4	0.1	0.1	0.1	54.9	56.5	53.6
Peritoneum, omentum & mesentery	0.4	0.1	0.5	0.2	0.1	0.3	34.3	39.9	33.7
Other digestive system	0.9	1.0	0.8	0.5	0.6	0.4	7.8	6.2	9.3
Respiratory System:	59.5	79.6	45.8	44.1	62.3	31.8	21.4	19.6	23.6
Nose, nasal cavity & middle ear	0.6	0.8	0.5	0.1	0.2	0.1	55.2	54.0	57.1
Larynx	3.9	7.3	1.4	1.6	3.0	0.5	51.7	52.6	48.7
Lung & bronchus	54.8	71.2	43.8	42.3	58.8	31.1	18.4	15.1	22.3
Pleura ^d	-	-	-	0.0	0.1	0.0	-	-	-
Trachea & other respiratory organs	0.2	0.2	0.1	0.1	0.1	0.0	49.9	47.2	55.3
Bones & joints	0.8	0.9	0.7	0.5	0.6	0.4	63.1	64.4	61.6
Soft tissue (including heart)	3.4	3.8	3.1	1.5	1.5	1.5	61.1	60.9	61.3
Skin (excl. basal & squamous):	2.1	2.3	2.0	0.8	1.1	0.5	82.2	77.8	85.5
Melanoma of the skin	1.0	1.1	0.9	0.3	0.4	0.3	66.7	59.5	72.1
Other non-epithelial skin	1.1	1.2	1.1	0.4	0.7	0.2	93.5	90.4	96.0
Breast	71.3	1.8	124.8	16.2	0.5	27.6	81.9	73.9	82.0
Breast (<i>in situ</i>)	18.6	0.2	33.0	-	-	-	100.0	95.2	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6 - continued
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Blacks								
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	28.2	-	49.8	11.0	-	18.9	56.9	-	56.9
Cervix uteri	4.8	-	8.7	1.9	-	3.4	55.6	-	55.6
Corpus uteri	14.9	-	26.2	2.1	-	3.6	65.1	-	65.1
Uterus, NOS	1.0	-	1.7	2.9	-	4.9	23.5	-	23.5
Ovary ^d	5.2	-	9.1	3.5	-	6.0	40.8	-	40.8
Vagina	0.5	-	0.9	0.2	-	0.3	44.3	-	44.3
Vulva	1.0	-	1.8	0.2	-	0.3	71.5	-	71.5
Other female genital system	0.8	-	1.3	0.2	-	0.3	52.3	-	52.3
Male Genital System:	75.7	178.2	-	14.2	38.3	-	96.0	96.0	-
Prostate	74.4	175.2	-	14.0	37.9	-	96.2	96.2	-
Testis	0.8	1.7	-	0.1	0.1	-	92.3	92.3	-
Penis	0.4	1.0	-	0.1	0.2	-	58.4	58.4	-
Other male genital system	0.1	0.3	-	0.0	0.1	-	68.7	68.7	-
Urinary System:	29.9	45.1	19.2	7.2	11.0	4.8	71.0	72.0	69.6
Urinary bladder	11.8	19.7	6.5	3.5	5.3	2.4	63.9	68.4	55.2
Kidney & renal pelvis	17.5	24.5	12.2	3.6	5.4	2.2	75.8	74.8	77.3
Ureter	0.2	0.3	0.2	0.0	0.0	0.0	28.8	21.1	33.2
Other urinary system	0.5	0.6	0.4	0.1	0.2	0.1	41.9	44.2	37.2
Eye & Orbit	0.3	0.3	0.3	0.0	0.0	0.0	88.1	85.4	90.1
Brain & Nervous System: ^e	3.9	4.5	3.3	2.6	3.2	2.2	38.9	37.2	40.7
Brain	3.5	4.2	3.0	-	-	-	35.0	33.6	36.5
Cranial nerves & other nervous system	0.3	0.4	0.3	-	-	-	77.0	77.0	76.4
Endocrine System:	10.5	5.0	15.2	0.9	0.8	0.9	94.3	87.2	96.1
Thyroid	9.5	4.0	14.3	0.5	0.4	0.6	97.2	92.8	97.9
Other endocrine & thymus	1.0	1.0	0.9	0.4	0.4	0.3	67.0	67.2	66.7
Lymphoma:	17.4	20.7	14.8	4.3	5.5	3.4	71.6	69.4	74.3
Hodgkin lymphoma	2.7	3.1	2.3	0.3	0.3	0.2	85.4	83.3	87.7
Non-Hodgkin lymphoma	14.7	17.7	12.5	4.0	5.2	3.2	68.4	66.0	71.2
Myeloma	13.8	16.5	12.0	6.2	7.5	5.3	56.8	56.3	57.3
Leukemia:	10.8	13.6	8.9	5.4	7.0	4.3	58.9	62.4	55.0
Lymphocytic:	4.5	6.1	3.4	1.4	1.9	1.1	75.4	78.6	71.2
Acute lymphocytic	1.0	1.1	0.9	0.3	0.4	0.3	65.2	66.4	63.6
Chronic lymphocytic	3.3	4.8	2.4	1.0	1.5	0.7	79.7	83.0	75.2
Other lymphocytic	0.2	0.3	0.1	0.1	0.1	0.1	69.0	73.5	55.0
Myeloid & Monocytic:	5.7	6.9	5.0	2.7	3.4	2.2	44.5	45.7	43.3
Acute myeloid	3.7	4.4	3.3	2.2	2.7	1.9	28.6	27.7	29.5
Chronic myeloid	1.8	2.2	1.5	0.3	0.4	0.2	71.6	72.7	70.2
Acute monocytic	0.1	0.2	0.1	0.0	0.0	-	24.3	29.1	21.0
Other myeloid & monocytic	0.1	0.2	0.1	0.2	0.3	0.1	38.3	42.0	31.2
Other leukemia:	0.6	0.6	0.6	1.3	1.7	1.0	41.6	45.1	37.2
Other acute leukemia	0.2	0.2	0.2	0.3	0.4	0.3	29.3	26.4	34.3
Aleukemic, subleukemic & NOS	0.4	0.4	0.4	1.0	1.2	0.8	48.0	55.9	39.3
Kaposi Sarcoma ^f	1.0	2.0	0.2	-	-	-	64.9	66.7	35.5
Mesothelioma ^f	0.5	0.9	0.2	-	-	-	15.3	10.9	22.1
Ill-defined & unspecified	8.1	9.3	7.3	12.6	16.1	10.3	12.9	13.1	13.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.


^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Figure 1.9

SEER Incidence^a and US Death Rates,^b 2013-2017 5-Year Relative Survival,^c 2010-2016 All Cancer Combined, by Race and Sex




^a Incidence rates are from the SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^b Death rates are from the US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

^c Survival rates are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Figure 1.11

5-Year Relative Survival (%) SEER Program, 2010-2016 Both Sexes, by Race and Cancer Site



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 2.8
All Cancer Sites (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	39	-	-	27	-	-
1970-1973 ^a	-	-	-	43	-	-	31	-	-
1975-1977 ^b	48.9	41.7	55.9	49.8	42.7	56.5	39.1	32.7	46.3
1978-1980 ^b	49.0	43.1	54.9	50.0	44.3	55.6	39.0	33.3	45.6
1981-1983 ^b	50.2	45.2	55.1	51.3	46.5	56.0	38.8	34.2	44.4
1984-1986 ^b	52.4	47.1	57.6	53.6	48.6	58.6	40.2	35.5	45.5
1987-1989 ^b	55.3	51.1	59.6	56.7	52.8	60.6	43.0	38.9	47.7
1990-1992 ^b	59.9	59.1	60.9	61.4	60.8	62.1	47.9	47.7	48.2
1993-1995 ^b	61.3	60.9	61.8	62.4	62.1	62.8	52.9	54.6	50.7
1996-1998 ^b	63.3	63.0	63.6	64.4	64.1	64.7	55.4	58.1	52.2
1999-2001 ^b	66.0	66.3	65.7	67.2	67.6	66.8	58.2	61.3	54.4
2002-2004 ^b	67.1	67.7	66.5	68.4	69.0	67.7	59.8	63.5	55.5
2005-2009 ^b	68.9	69.5	68.3	70.0	70.6	69.5	62.6	65.9	58.8
2010-2016 ^b	69.5 ^e	68.6 ^e	70.5 ^e	70.5 ^e	69.5 ^e	71.5 ^e	64.1 ^e	66.1 ^e	62.1 ^e
5-Year Period Survival (Percent) ^{cd}									
2016	67.7	66.3	69.1	68.0	66.2	69.7	63.0	64.4	61.4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	83.3	79.4	85.8	84.6	80.9	87.0	74.1	69.2	76.9
Ages 45-54	75.3	69.7	79.6	76.0	70.0	80.7	68.6	67.5	69.6
Ages 55-64	70.1	68.6	71.9	70.9	69.0	73.1	63.8	65.5	61.4
Ages 65-74	67.4	68.8	65.6	67.7	68.7	66.4	62.5	66.8	56.7
Ages 75+	50.8	52.8	49.0	51.5	52.9	50.1	44.4	48.7	41.1
Ages <65	74.3	70.6	77.7	75.1	71.1	78.8	67.0	66.5	67.6
Ages 65+	60.1	62.4	57.5	60.4	62.2	58.3	55.8	61.2	49.8

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.
^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
Based on follow-up of patients into 2017.
^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).
^e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).
^f The standard error is between 5 and 10 percentage points.
^g The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 3.8
Cancer of the Brain and Other Nervous System (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	18	16	21	19	17	21
1970-1973 ^a	-	-	-	20	18	22	19	19	19
1975-1977 ^b	22.5	20.7	24.8	21.9	20.2	24.1	24.9	19.6	33.6 ^g
1978-1980 ^b	23.6	22.4	25.1	23.0	22.0	24.4	28.2	28.7	27.5
1981-1983 ^b	24.2	23.1	25.5	23.4	22.5	24.6	30.8	31.7	29.2 ^g
1984-1986 ^b	26.9	25.6	28.5	26.2	24.8	27.9	30.9	32.8	28.5
1987-1989 ^b	29.0	27.4	31.0	28.3	26.4	30.8	31.9	34.0	29.3
1990-1992 ^b	30.1	30.5	29.7	29.1	29.4	28.8	39.3	40.2	38.1
1993-1995 ^b	32.2	33.0	31.3	30.9	31.4	30.2	41.9	46.1	37.3
1996-1998 ^b	31.3	30.7	32.0	30.6	30.2	31.0	36.0	33.7	38.3
1999-2001 ^b	34.0	31.0	37.9	33.2	30.4	36.7	38.4	33.0	45.6
2002-2004 ^b	35.1	34.2	36.2	34.2	33.8	34.6	39.5	33.4	45.8
2005-2009 ^b	35.8	34.5	37.3	34.2	33.0	35.7	43.1	41.1	44.8
2010-2016 ^b	33.4 ^f	31.9 ^f	35.3 ^f	32.1 ^f	30.7 ^f	34.0 ^f	39.5 ^f	38.1 ^f	41.0
5-Year Period Survival (Percent) ^{cd}									
2016	31.8	30.1	33.9	30.4	28.7	32.7	37.2	35.2	39.4
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	34,955	19,533	15,422	29,753	16,714	13,039	2,533	1,352	1,181
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	77	77	77	77	78	77	75	77	74
Regional	15	15	15	15	15	15	15	14	16
Distant	2	3	2	2	2	2	3	3	4
Unstaged/Unknown	6	5	6	5	5	6	7	7	7
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	69.1	66.9	72.0	69.8	67.7	72.5	66.1	63.0	69.5
Ages 45-54	31.4	28.6	35.4	31.2	28.4	35.3	27.0	23.2	32.2
Ages 55-64	15.5	14.0	17.6	14.9	13.5	16.8	16.2	14.9	18.0
Ages 65-74	9.2	7.7	11.1	8.9	7.0	11.3	11.6	14.4	8.8
Ages 75+	4.3	4.2	4.4	3.9	3.8	3.9	9.5	10.8	7.9
Ages <65	44.5	41.9	48.2	43.6	41.0	47.2	46.4	42.6	50.8
Ages 65+	7.0	6.3	7.9	6.6	5.7	7.7	11.1	13.8	8.6
Stage ^e :									
All Stages	32.6	31.3	34.2	31.3	30.0	33.0	38.9	37.2	40.7
Localized	35.3	34.0	36.8	34.0	32.7	35.7	40.5	39.6	41.6
Regional	20.3	19.2	21.7	19.1	18.3	20.1	26.9	21.3	32.4
Distant	32.7	29.4	37.2	30.9	27.9	35.2	43.5 ^g	39.3 ^g	47.6 ^g
Unstaged/Unknown	29.0	26.6	31.7	26.3	23.8	29.1	44.0	40.7 ^g	47.6 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 4.13
Cancer of the Female Breast (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	63	-	-	46	-	-
1970-1973 ^a	-	-	-	68	-	-	51	-	-
1975-1977 ^b	74.8	76.5	74.3	75.6	77.8	74.9	62.2	62.4	62.0
1978-1980 ^b	74.4	75.5	74.1	75.1	76.1	74.9	63.4	67.0	61.5
1981-1983 ^b	76.1	77.4	75.7	77.1	78.6	76.7	63.4	65.0	62.6
1984-1986 ^b	78.9	77.8	79.3	80.0	79.5	80.1	65.1	64.0	65.9
1987-1989 ^b	84.0	81.4	84.9	85.1	82.7	85.9	71.1	69.6	71.9
1990-1992 ^b	85.2	83.4	85.9	86.5	85.1	86.9	71.5	70.1	72.4
1993-1995 ^b	86.4	84.3	87.1	87.6	86.2	88.1	72.8	70.5	74.2
1996-1998 ^b	88.2	86.6	88.8	89.3	88.3	89.7	76.3	74.1	77.6
1999-2001 ^b	89.7	88.1	90.3	90.8	89.9	91.1	79.0	77.0	80.1
2002-2004 ^b	90.0	89.3	90.2	91.4	91.1	91.5	78.0	77.6	78.2
2005-2009 ^b	90.9	91.2	90.9	92.2	92.5	92.1	81.2	82.4	80.6
2010-2016 ^b	91.4 ^f	91.2 ^f	91.5 ^f	92.5 ^f	92.5 ^f	92.5 ^f	83.4 ^f	82.6 ^f	83.8 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	90.3	90.0	90.4	91.2	91.1	91.2	82.6	81.5	83.0
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	356,026	79,017	277,009	278,199	57,351	220,848	40,580	10,659	29,921
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	63	55	65	64	55	66	55	48	57
Regional	30	39	27	29	38	27	35	42	32
Distant	6	5	6	6	5	6	9	9	9
Unstaged/Unknown	2	1	2	1	1	2	2	2	2
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	88.1	-	-	89.3	-	-	79.2	-	-
Ages 45-54	91.1	-	-	92.2	-	-	82.8	-	-
Ages 55-64	90.5	-	-	91.5	-	-	83.0	-	-
Ages 65-74	92.1	-	-	92.8	-	-	85.3	-	-
Ages 75+	86.0	-	-	87.0	-	-	76.8	-	-
Ages <65	90.2	-	-	91.3	-	-	82.1	-	-
Ages 65+	89.7	-	-	90.4	-	-	82.0	-	-
Stage ^e :									
All Stages	90.0	89.7	90.1	90.9	90.9	90.9	82.0	81.1	82.4
Localized	98.9	97.1	99.3	99.2	97.4	99.6	96.1	94.0	96.8
Regional	85.7	87.3	85.0	86.8	88.6	86.1	77.7	78.6	77.3
Distant	28.1	37.6	25.6	29.4	40.8	26.8	19.4	26.2	16.9
Unstaged/Unknown	55.1	75.1	50.4	52.7	74.9	48.5	50.3	69.6	43.0
<i>In Situ</i> ^j	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.9	100.0

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates

from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

^j *In situ* cases are not included in the All Stages group.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 5.8
Cancer of the Cervix Uteri (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	58	-	-	47	-	-
1970-1973 ^a	-	-	-	64	-	-	61	-	-
1975-1977 ^b	69.1	82.6	57.8	69.7	84.0	58.1	64.7	75.6	55.1
1978-1980 ^b	67.4	78.4	57.8	68.1	79.8	58.2	61.1	70.7	51.9
1981-1983 ^b	66.9	79.6	54.6	67.8	80.8	54.9	59.2	73.6	46.2
1984-1986 ^b	67.2	77.9	55.3	68.8	79.4	56.4	57.8	68.0	48.1
1987-1989 ^b	70.0	79.6	58.0	72.5	82.6	58.4	56.9	62.7	51.8
1990-1992 ^b	69.7	79.2	56.8	71.0	81.4	56.4	58.1	63.8	51.0
1993-1995 ^b	72.6	81.8	59.9	74.2	83.5	60.1	62.8	70.6	53.6
1996-1998 ^b	72.7	81.0	60.5	73.7	82.7	59.2	65.2	67.8	62.1
1999-2001 ^b	72.4	84.0	56.2	73.3	85.7	54.9	66.2	74.1	56.9
2002-2004 ^b	69.3	79.3	55.8	70.3	81.3	54.5	64.5	72.3	54.8
2005-2009 ^b	70.0	80.2	56.7	71.4	82.6	56.1	61.1	67.2	54.8
2010-2016 ^b	69.7	79.9 ^f	57.5	71.5	82.2	58.4	57.9 ^f	69.0	46.5 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	65.9	76.5	54.3	66.8	77.3	54.6	56.6	67.6	46.7
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	21,862	11,432	10,430	16,243	8,707	7,536	3,003	1,412	1,591
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	44	57	31	46	58	32	36	45	27
Regional	36	30	42	35	30	41	40	38	42
Distant	16	10	22	15	9	22	19	13	25
Unstaged/Unknown	4	3	5	4	3	5	5	4	5
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	78.5	-	-	79.9	-	-	68.0	-	-
Ages 45-54	66.8	-	-	68.1	-	-	58.2	-	-
Ages 55-64	57.6	-	-	58.2	-	-	46.3	-	-
Ages 65-74	52.4	-	-	52.3	-	-	48.1	-	-
Ages 75+	34.7	-	-	35.9	-	-	27.5	-	-
Ages <65	70.4	-	-	71.8	-	-	59.7	-	-
Ages 65+	45.4	-	-	46.1	-	-	39.4	-	-
Stage ^e :									
All Stages	66.1	76.2	54.8	67.5	77.8	55.5	55.6	65.8	46.1
Localized	91.8	93.9	87.7	92.3	94.4	87.9	87.6	90.8	82.3
Regional	57.6	62.2	53.9	58.8	63.9	54.5	49.7	54.7	45.5
Distant	16.8	19.6	15.4	18.2	21.9	16.4	10.5	9.9	11.1
Unstaged/Unknown	49.7	72.7	33.9	49.1	73.3	31.7	47.4	64.8 ^g	36.2 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 6.12
Cancer of the Colon and Rectum (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	49.8	48.9	50.6	50.1	49.3	50.8	44.8	43.4	46.0
1978-1980 ^b	51.2	50.2	52.1	51.6	50.6	52.5	45.4	43.4	46.9
1981-1983 ^b	54.0	53.7	54.2	54.3	54.3	54.3	46.5	42.9	49.5
1984-1986 ^b	57.7	57.7	57.6	58.4	58.5	58.3	48.4	47.5	49.1
1987-1989 ^b	59.6	59.8	59.3	60.0	60.6	59.5	52.3	49.8	54.5
1990-1992 ^b	61.2	61.0	61.3	61.9	61.7	62.1	52.8	54.4	51.4
1993-1995 ^b	59.9	59.7	60.0	60.5	60.3	60.6	51.8	51.4	52.0
1996-1998 ^b	62.4	62.3	62.4	63.0	62.8	63.1	54.0	55.3	53.0
1999-2001 ^b	65.1	66.1	64.1	66.5	67.4	65.6	54.4	56.0	53.1
2002-2004 ^b	65.8	65.7	65.8	66.7	67.1	66.4	56.6	55.5	57.5
2005-2009 ^b	66.7	66.8	66.6	67.5	67.8	67.1	59.5	57.4	61.2
2010-2016 ^b	66.1 ^f	66.0 ^f	66.3 ^f	66.8 ^f	66.8 ^f	66.8 ^f	59.6 ^f	59.0 ^f	60.1 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	65.0	64.4	65.6	65.3	64.8	65.9	59.3	57.1	61.5
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	208,239	108,775	99,464	159,506	83,851	75,655	26,058	12,807	13,251
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	38	38	38	38	38	38	37	36	38
Regional	35	35	35	36	36	36	32	32	32
Distant	22	22	22	22	22	21	26	27	25
Unstaged/Unknown	4	4	5	4	4	5	5	5	5
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	69.5	67.7	71.4	70.5	68.6	72.5	63.0	58.9	66.6
Ages 45-54	71.2	69.5	73.4	71.5	69.8	73.8	65.4	62.2	68.6
Ages 55-64	67.0	65.7	68.8	67.7	66.4	69.7	60.1	58.4	62.2
Ages 65-74	66.4	65.0	68.1	66.7	65.5	68.2	59.6	55.8	63.4
Ages 75+	55.2	55.1	55.2	56.3	56.3	56.3	46.2	43.7	46.9
Ages <65	68.9	67.3	70.9	69.5	67.9	71.6	62.4	59.8	65.3
Ages 65+	60.5	60.4	60.5	61.0	61.0	61.0	53.7	51.8	55.1
Stage ^e :									
All Stages	64.6	64.0	65.1	65.0	64.5	65.5	58.8	56.8	60.6
Localized	90.2	89.4	90.9	90.3	89.5	91.3	87.4	86.2	88.4
Regional	71.8	71.5	72.0	72.3	72.2	72.3	67.5	65.6	69.2
Distant	14.3	13.3	15.5	14.9	13.9	16.0	10.5	9.4	11.6
Unstaged/Unknown	37.5	41.1	34.0	33.4	37.6	29.4	39.7	40.0	39.0

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 6.13
Cancer of the Colon (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	43	42	44	34	32	35
1970-1973 ^a	-	-	-	49	47	50	37	36	38
1975-1977 ^b	50.6	50.1	51.1	50.9	50.5	51.3	44.9	44.2	45.5
1978-1980 ^b	52.3	51.2	53.1	52.4	51.3	53.4	48.9	47.5	49.8
1981-1983 ^b	55.2	55.6	54.7	55.4	56.2	54.7	48.5	44.7	51.5
1984-1986 ^b	58.3	58.8	57.8	59.0	59.6	58.5	49.2	48.9	49.3
1987-1989 ^b	60.2	60.7	59.6	60.6	61.4	59.9	52.3	50.6	53.8
1990-1992 ^b	62.0	62.3	61.7	62.7	63.1	62.4	53.3	54.6	52.3
1993-1995 ^b	59.8	60.1	59.5	60.5	60.7	60.2	51.2	51.3	50.9
1996-1998 ^b	62.1	62.3	61.8	62.8	62.8	62.8	53.7	56.0	51.8
1999-2001 ^b	64.9	66.1	63.7	66.6	67.9	65.5	52.8	54.3	51.6
2002-2004 ^b	64.8	64.6	64.9	65.7	65.7	65.7	55.6	55.1	56.0
2005-2009 ^b	66.0	66.4	65.6	67.2	67.8	66.7	57.2	56.4	57.9
2010-2016 ^b	64.7 ^f	64.9 ^f	64.5 ^f	65.9 ^f	66.1 ^f	65.7 ^f	56.5 ^f	57.4 ^f	55.8 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	63.8	63.5	64.0	64.6	64.2	64.9	57.3	56.3	58.3
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	143,414	71,337	72,077	110,171	55,150	55,021	18,939	8,949	9,990
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	37	38	37	38	38	37	35	34	35
Regional	36	35	36	36	35	36	34	33	34
Distant	23	23	23	23	23	22	28	29	27
Unstaged/Unknown	4	4	4	4	3	4	4	4	4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	68.7	66.7	70.5	70.4	68.1	72.8	60.5	57.3	63.0
Ages 45-54	68.4	67.6	69.3	69.3	68.4	70.3	61.1	60.1	62.1
Ages 55-64	65.6	64.9	66.5	66.6	65.7	67.7	58.4	57.9	58.9
Ages 65-74	66.3	64.9	67.8	66.8	65.4	68.3	59.4	57.0	61.7
Ages 75+	56.3	56.3	56.3	57.7	57.7	57.7	47.5	44.9	48.2
Ages <65	67.0	66.0	68.1	68.1	66.9	69.4	59.6	58.6	60.7
Ages 65+	60.7	60.6	60.7	61.5	61.4	61.5	54.0	52.9	54.8
Stage ^e :									
All Stages	63.4	63.2	63.6	64.2	63.9	64.5	57.0	56.2	57.7
Localized	90.6	89.8	91.3	91.0	90.0	92.0	87.2	86.9	87.4
Regional	71.7	71.9	71.5	72.1	72.6	71.7	68.7	68.0	69.3
Distant	13.7	12.8	14.7	14.2	13.3	15.2	10.1	9.2	10.9
Unstaged/Unknown	27.8	32.8	23.6	25.8	31.3	21.3	29.1	31.8	26.0

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.
^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
Based on follow-up of patients into 2017.
^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).
^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.
^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).
^g The standard error is between 5 and 10 percentage points.
^h The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 6.14
Cancer of the Rectum (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	38	36	41	27	28	27
1970-1973 ^a	-	-	-	45	43	48	30	20	40
1975-1977 ^b	48.1	46.9	49.5	48.3	47.3	49.4	44.4	41.4	46.8
1978-1980 ^b	48.9	48.3	49.5	49.7	49.3	50.2	34.8	33.5	35.8
1981-1983 ^b	51.3	50.0	52.8	51.9	50.8	53.2	40.3	38.2	42.5
1984-1986 ^b	56.2	55.5	57.1	56.9	56.3	57.7	46.0	43.4	48.5
1987-1989 ^b	58.2	57.9	58.5	58.7	58.9	58.4	52.3	47.7	56.9
1990-1992 ^b	59.2	58.4	60.3	59.9	59.0	61.1	51.2	53.7	48.5
1993-1995 ^b	60.1	59.0	61.5	60.5	59.5	61.8	53.8	51.5	56.4
1996-1998 ^b	63.2	62.5	64.2	63.5	62.9	64.3	55.1	53.5	56.4
1999-2001 ^b	65.8	66.2	65.4	66.5	66.6	66.3	59.7	60.9	58.3
2002-2004 ^b	68.3	68.1	68.7	69.4	70.0	68.6	59.8	56.8	62.7
2005-2009 ^b	68.3	67.5	69.3	68.3	68.0	68.6	65.5	59.9	71.0
2010-2016 ^b	69.2 ^f	67.9 ^f	70.9 ^f	68.8 ^f	68.0 ^f	69.9 ^f	67.5 ^f	62.9 ^f	72.6 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	67.6	66.0	69.8	67.0	65.8	68.8	64.6	59.0	71.1
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	64,825	37,438	27,387	49,335	28,701	20,634	7,119	3,858	3,261
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	40	39	42	39	38	40	45	41	49
Regional	35	36	33	37	38	35	28	30	25
Distant	19	20	19	20	20	19	21	23	18
Unstaged/Unknown	6	5	6	5	4	5	7	6	7
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	70.9	69.1	73.1	70.7	69.5	72.2	68.3	61.8	74.8
Ages 45-54	75.2	71.9	79.8	74.7	71.6	79.1	73.5	66.0	82.0
Ages 55-64	69.4	66.9	73.5	69.6	67.3	73.5	64.4	59.6	71.6
Ages 65-74	66.8	65.2	69.2	66.5	65.6	67.9	60.1	52.0	69.5
Ages 75+	50.8	51.4	50.2	51.2	51.8	50.5	40.2	38.7	40.4
Ages <65	71.9	69.1	76.0	71.7	69.2	75.5	68.5	62.3	76.5
Ages 65+	59.7	59.9	59.6	59.6	60.1	58.9	52.6	48.3	56.6
Stage ^e :									
All Stages	67.1	65.6	69.1	66.7	65.6	68.2	63.4	58.3	69.4
Localized	89.4	88.8	90.1	89.0	88.6	89.5	87.8	85.1	90.5
Regional	71.9	70.7	73.6	72.6	71.5	74.1	63.5	59.5	69.0
Distant	15.8	14.4	17.9	16.5	15.2	18.3	12.0	10.2	14.7
Unstaged/Unknown	52.4	51.8	53.1	46.7	46.8	46.5	55.0	50.8	59.1

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 7.8
Cancer of the Corpus and Uterus, NOS (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	73	-	-	31	-	-
1970-1973 ^a	-	-	-	81	-	-	44	-	-
1975-1977 ^b	86.9	92.7	86.2	88.0	93.3	87.4	60.3	84.4 ^g	55.8
1978-1980 ^b	82.5	91.7	81.3	83.7	93.1	82.6	54.9	82.3 ^g	49.5
1981-1983 ^b	80.7	91.2	79.4	82.2	92.3	81.1	50.7	82.8 ^g	45.6
1984-1986 ^b	82.5	93.6	81.0	84.0	93.9	82.8	56.2	83.5 ^g	52.7
1987-1989 ^b	82.2	89.8	81.1	83.9	90.9	82.9	56.7	82.8 ^g	52.9
1990-1992 ^b	83.6	90.1	82.6	85.8	92.2	84.9	54.0	72.9 ^g	50.2
1993-1995 ^b	83.2	90.0	82.0	84.9	91.5	83.8	58.6	81.7	54.0
1996-1998 ^b	83.5	90.1	82.4	85.2	91.3	84.2	61.7	82.2	57.3
1999-2001 ^b	84.2	88.8	83.3	85.9	89.9	85.2	61.4	71.2	58.9
2002-2004 ^b	83.0	90.1	81.5	85.3	92.5	84.0	60.4	78.0	55.9
2005-2009 ^b	83.6	88.3	82.7	85.7	89.8	85.1	65.8	76.4	63.8
2010-2016 ^b	82.9 ^f	89.2 ^f	82.0 ^f	85.5 ^f	90.4 ^f	84.9 ^f	64.8 ^f	82.2	62.1 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	81.3	88.6	80.1	83.5	89.4	82.7	63.9	80.3	61.5
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	82,453	11,188	71,265	65,045	8,149	56,896	8,948	1,105	7,843
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	67	71	67	69	73	68	54	62	53
Regional	20	17	21	20	17	20	24	19	25
Distant	9	8	9	8	7	8	17	14	17
Unstaged/Unknown	3	4	3	3	4	3	5	5	5
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	89.6	-	-	90.5	-	-	81.6	-	-
Ages 45-54	86.3	-	-	87.7	-	-	72.0	-	-
Ages 55-64	83.9	-	-	86.6	-	-	65.6	-	-
Ages 65-74	78.5	-	-	81.7	-	-	57.2	-	-
Ages 75+	67.6	-	-	70.4	-	-	44.8	-	-
Ages <65	85.3	-	-	87.3	-	-	69.1	-	-
Ages 65+	74.8	-	-	77.9	-	-	53.5	-	-
Stage ^e :									
All Stages	81.2	88.2	80.1	83.5	89.3	82.7	62.7	79.1	60.3
Localized	95.0	96.6	94.7	95.9	96.9	95.7	86.5	92.9	85.4
Regional	69.4	81.5	67.8	72.0	82.7	70.7	49.9	71.7	47.3
Distant	17.3	30.5	15.5	18.8	31.4	17.1	10.4	26.6	8.5
Unstaged/Unknown	53.2	87.3	46.3	52.2	87.8	46.2	44.5	79.8 ^g	38.9

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 8.8
Cancer of the Esophagus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	4	4	6	1	0	2
1970-1973 ^a	-	-	-	4	4	4	4	4	3
1975-1977 ^b	5.0	4.0	7.5	5.5	4.8	7.0	3.5	2.0	7.7
1978-1980 ^b	5.0	4.8	5.6	5.3	5.3	5.2	4.3	3.4	6.8
1981-1983 ^b	6.7	6.1	8.2	7.3	6.5	9.0	4.6	4.0	6.5
1984-1986 ^b	9.6	8.4	12.2	10.3	9.0	13.2	8.7	8.2	9.9
1987-1989 ^b	9.4	9.4	9.4	10.5	11.1	9.0	6.6	5.3	10.2
1990-1992 ^b	12.2	11.7	13.4	12.9	12.2	14.8	9.4	9.7	8.4
1993-1995 ^b	12.1	12.2	11.7	13.3	13.6	12.7	7.6	7.8	6.9
1996-1998 ^b	13.4	13.1	14.4	14.2	14.1	14.7	10.2	8.5	13.6
1999-2001 ^b	18.0	17.7	19.3	18.8	18.6	19.7	12.4	10.6	16.2
2002-2004 ^b	18.2	18.0	18.9	19.6	19.6	19.5	10.4	8.0	14.9
2005-2009 ^b	20.1	20.2	19.5	21.1	21.3	20.1	14.0	13.2	15.4
2010-2016 ^b	21.3 ^f	20.6 ^f	24.1 ^f	22.2 ^f	21.6 ^f	24.9 ^f	13.1 ^f	12.0 ^f	14.8 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	20.4	19.6	23.6	20.9	20.2	23.8	15.6	14.7	17.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	21,743	17,264	4,479	18,248	14,746	3,502	2,163	1,488	675
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	18	17	21	18	18	22	16	14	20
Regional	33	33	33	33	33	32	33	33	33
Distant	39	41	33	39	41	32	40	43	34
Unstaged/Unknown	10	9	14	9	8	14	11	10	13
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	23.1	21.1	31.0	23.1	22.8	24.3 ^g	20.0 ^g	-	-
Ages 45-54	21.3	20.1	27.5	22.2	21.1	29.0	15.1	14.5	16.2
Ages 55-64	20.4	19.4	25.6	21.7	20.8	27.4	12.9	10.2	19.3
Ages 65-74	23.4	22.4	27.8	24.3	23.2	29.5	15.1	13.6	17.8
Ages 75+	13.9	13.8	14.3	13.6	13.6	13.7	12.0	12.2	11.3
Ages <65	20.8	19.7	26.5	22.0	21.0	27.7	13.9	11.4	20.0
Ages 65+	19.2	18.9	20.2	19.6	19.3	20.4	14.1	13.3	15.1
Stage ^e :									
All Stages	19.9	19.3	22.6	20.6	20.1	22.8	14.0	12.2	17.7
Localized	47.1	49.2	40.6	48.6	50.9	40.8	32.2	29.6	35.7 ^g
Regional	25.2	24.3	29.3	25.9	25.0	29.7	19.8	18.4	22.0
Distant	4.9	4.2	8.5	4.9	4.4	8.2	3.3	2.2	6.0
Unstaged/Unknown	12.8	12.9	12.7	12.7	12.7	12.6	10.2	10.5	10.1

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 9.8
Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	40	34	48	-	-	-
1970-1973 ^a	-	-	-	67	66	69	-	-	-
1975-1977 ^b	71.8	69.9	74.3	72.1	70.1	74.5	70.1	68.5 ^g	73.3 ^g
1978-1980 ^b	71.6	70.3	73.4	71.7	69.8	74.2	70.6	74.7 ^g	63.1 ^g
1981-1983 ^b	74.3	72.9	76.0	74.6	73.7	75.7	71.8	69.6 ^g	75.9 ^g
1984-1986 ^b	78.4	76.6	80.7	78.8	77.0	81.2	74.9	76.0 ^g	72.1 ^g
1987-1989 ^b	79.2	76.6	82.5	79.7	76.8	83.3	72.3	70.9 ^g	74.0 ^g
1990-1992 ^b	81.7	79.3	84.6	82.8	81.1	84.9	74.3	65.2	84.3
1993-1995 ^b	81.7	79.3	84.6	82.2	80.0	84.7	78.4	74.2	83.0
1996-1998 ^b	85.2	84.5	85.9	85.8	84.5	87.3	81.2	84.4	77.7
1999-2001 ^b	85.1	82.8	87.9	85.7	84.0	87.8	81.6	75.6	89.7
2002-2004 ^b	86.2	85.2	87.2	87.7	86.9	88.5	79.2	74.4	82.8
2005-2009 ^b	88.2	87.2	89.5	88.7	88.3	89.3	85.3	81.2	90.0
2010-2016 ^b	89.6 ^f	88.3 ^f	91.3 ^f	90.3 ^f	89.1 ^f	91.7 ^f	86.7 ^f	83.5 ^f	90.8 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	87.5	86.5	88.9	87.9	86.8	89.4	84.5	83.0	86.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	14,617	8,122	6,495	11,580	6,436	5,144	1,902	1,048	854
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	14	15	13	14	15	13	15	15	15
Regional	39	35	45	41	36	47	31	26	37
Distant	42	45	37	41	44	36	51	56	44
Unstaged/Unknown	5	5	4	4	5	4	3	3	3
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	95.1	94.6	95.7	95.8	95.5	96.2	90.7	88.2	93.4
Ages 45-54	87.2	85.2	90.6	88.5	86.9	91.2	81.8	78.8	85.8
Ages 55-64	79.5	78.2	81.4	80.5	79.4	81.8	70.1	66.6 ^g	73.7 ^g
Ages 65-74	67.0	64.1	70.8	66.4	62.8	71.0	72.8 ^g	75.5 ^g	67.9 ^g
Ages 75+	49.4	50.8	48.0	49.5	49.3	49.3	52.9 ^g	-	-
Ages <65	91.9	90.7	93.4	92.7	91.7	93.9	86.7	84.0	90.0
Ages 65+	59.6	59.0	60.1	59.2	57.5	60.8	67.9 ^g	73.6 ^g	61.5 ^g
Stage ^e :									
All Stages	87.4	86.5	88.6	87.5	86.6	88.6	85.4	83.3	87.7
Localized	91.3	92.2	90.0	91.1	91.8	90.0	90.9	92.4	88.8
Regional	93.8	92.7	94.9	93.9	92.7	95.0	92.8	90.4	94.3
Distant	80.6	80.4	80.8	80.7	80.8	80.4	79.2	76.9	82.8
Unstaged/Unknown	81.3	79.1	83.9	79.7	76.1	84.5	78.3 ^g	84.1 ^g	71.8 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^d SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^e Based on follow-up of patients into 2017.^f Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^g Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^h The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).⁻ The standard error is between 5 and 10 percentage points.⁻ The standard error is greater than 10 percentage points.⁻ Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 10.6
Kaposi Sarcoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	80.7 ^f	80.1 ^f	-	79.9 ^f	79.0 ^f	-	-	-	-
1978-1980 ^b	78.3 ^f	79.4 ^f	73.1 ^g	78.0 ^f	78.4 ^f	72.5 ^g	-	-	-
1981-1983 ^b	35.7	33.4	64.3 ^g	34.0	31.6	64.2 ^g	-	-	-
1984-1986 ^b	13.0	11.7	70.5 ^g	12.8	11.4	70.2 ^g	16.8	15.7	-
1987-1989 ^b	9.9	9.3	68.5 ^g	9.4	8.8	72.4 ^g	12.4	11.3	-
1990-1992 ^b	9.3	8.6	53.9 ^f	8.9	8.2	55.4 ^f	11.8	10.8	-
1993-1995 ^b	21.8	21.1	53.8 ^f	22.1	21.3	62.1 ^g	17.5	16.7	-
1996-1998 ^b	52.4	51.6	71.4 ^g	57.1	55.9	85.9 ^f	40.2	39.7	-
1999-2001 ^b	58.3	57.9	60.0 ^f	64.8	63.3	78.4 ^g	44.1	45.6	-
2002-2004 ^b	64.7	63.8	71.1 ^g	75.2	74.1	76.9 ^g	42.0	42.2	-
2005-2009 ^b	74.3	74.5	70.7 ^f	81.4	81.5	76.0 ^f	59.8	60.2	-
2010-2016 ^b	76.3 ^e	76.2	75.3 ^f	82.0	81.1	83.7 ^f	66.0	67.6	37.9 ^g
5-Year Period Survival (Percent) ^{cd}									
2016	74.6	73.8	80.7	77.6	75.5	90.7	63.5	65.3	33.4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	68.4	69.1	46.2 ^f	70.3	70.3	-	64.4	65.5	39.1 ^g
Ages 45-54	73.1	73.6	-	75.9	75.7	-	61.9	64.1	-
Ages 55-64	81.4	82.1	-	83.0	82.4	-	75.3 ^f	82.6 ^f	-
Ages 65-74	84.7	83.4	85.4 ^f	82.7	80.3	87.9 ^f	-	-	-
Ages 75+	85.2	76.9 ^f	86.0 ^f	85.9 ^f	77.1 ^f	86.9 ^f	-	-	-
Ages <65	71.6	72.2	55.0 ^f	74.6	74.3	82.2 ^f	64.6	66.3	34.0 ^f
Ages 65+	85.7	81.2	86.6	85.2	79.6	87.9 ^f	65.7 ^g	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.
^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.
^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.
Based on follow-up of patients into 2017.
^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).
^e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).
^f The standard error is between 5 and 10 percentage points.
^g The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 11.8
Cancer of the Kidney and Renal Pelvis (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	37	36	39	38	38	37
1970-1973 ^a	-	-	-	46	44	50	44	40	49
1975-1977 ^b	50.1	50.2	49.8	49.8	50.1	49.3	48.8	47.9	50.4 ^g
1978-1980 ^b	52.9	52.7	53.3	52.6	52.9	52.1	56.9	51.9	62.8 ^g
1981-1983 ^b	50.1	51.1	48.3	49.9	51.2	47.7	50.6	50.2	51.2
1984-1986 ^b	54.5	55.0	53.7	54.6	55.3	53.5	52.6	49.2	57.5
1987-1989 ^b	56.7	57.0	56.1	57.3	58.0	56.1	54.8	53.0	57.0
1990-1992 ^b	60.2	60.5	59.6	60.6	61.2	59.7	57.0	55.2	59.1
1993-1995 ^b	61.5	61.7	61.1	62.0	62.9	60.7	57.6	54.2	62.1
1996-1998 ^b	62.6	62.9	62.0	62.1	62.6	61.2	67.1	68.2	64.8
1999-2001 ^b	64.9	63.4	67.2	64.9	63.7	66.9	64.1	59.4	69.4
2002-2004 ^b	69.3	69.5	68.9	69.4	69.8	68.7	65.7	65.0	66.7
2005-2009 ^b	74.8	74.0	76.2	74.8	74.0	76.2	74.6	73.6	76.1
2010-2016 ^b	75.9 ^f	75.2 ^f	76.9 ^f	75.7 ^f	75.0 ^f	76.7 ^f	77.9 ^f	77.5 ^f	78.6 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	75.8	75.0	77.0	75.8	74.9	77.3	75.8	75.2	76.8
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	81,354	51,159	30,195	65,643	41,603	24,040	9,564	5,664	3,900
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	65	63	68	64	63	67	72	70	74
Regional	16	18	15	17	18	15	12	12	11
Distant	16	16	14	16	17	14	14	15	12
Unstaged/Unknown	3	3	3	3	3	3	3	3	3
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	88.4	86.7	91.0	90.1	88.6	92.2	80.5	76.3	86.7
Ages 45-54	81.9	80.3	85.0	81.6	79.8	85.2	82.1	81.4	83.5
Ages 55-64	76.6	75.0	79.5	76.6	75.2	79.5	76.0	73.6	79.9
Ages 65-74	74.0	72.9	75.9	74.0	72.8	76.0	74.7	73.8	75.7
Ages 75+	59.2	60.4	57.7	59.2	60.2	57.9	59.6	58.4	59.8
Ages <65	80.5	78.7	83.7	80.6	78.9	84.0	78.9	76.7	82.5
Ages 65+	68.1	68.4	67.5	68.0	68.2	67.7	69.7	69.8	69.3
Stage ^e :									
All Stages	75.2	74.5	76.3	75.1	74.4	76.2	75.8	74.8	77.3
Localized	92.6	92.6	92.5	92.7	92.6	92.9	91.8	92.4	91.0
Regional	70.4	71.4	68.3	71.2	72.4	68.9	60.5	59.2	62.7
Distant	13.0	13.0	12.9	13.1	13.3	12.6	10.8	8.8	14.2
Unstaged/Unknown	42.3	42.4	42.0	39.7	39.6	39.7	51.1	56.3 ^g	44.8 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 12.8
Cancer of the Larynx (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	53	54	46	-	-	-
1970-1973 ^a	-	-	-	62	63	56	-	-	-
1975-1977 ^b	66.0	66.6	62.5	66.7	67.4	62.3	58.2	57.1	63.3 ^g
1978-1980 ^b	65.3	65.5	64.6	66.2	66.4	65.4	56.9	57.2	55.8 ^g
1981-1983 ^b	68.1	68.4	66.9	69.5	69.7	68.5	56.5	57.7	50.8 ^g
1984-1986 ^b	65.2	65.7	62.2	66.9	67.4	64.0	53.3	53.7	51.1 ^g
1987-1989 ^b	65.5	66.6	61.0	67.0	68.5	60.8	56.1	54.3	61.3 ^g
1990-1992 ^b	65.8	66.7	62.6	67.7	68.4	64.6	53.7	54.3	51.3 ^g
1993-1995 ^b	63.6	65.2	56.6	65.2	67.0	57.9	53.1	54.4	47.4 ^g
1996-1998 ^b	64.8	66.5	58.8	66.8	68.4	61.2	53.7	56.6	45.0 ^g
1999-2001 ^b	63.3	64.2	59.8	65.3	66.3	61.1	49.8	49.1	52.4 ^g
2002-2004 ^b	61.8	62.1	60.7	64.3	64.2	64.9	50.8	53.6	41.4 ^g
2005-2009 ^b	63.1	63.5	61.2	65.1	65.6	63.1	50.9	51.1	49.7 ^g
2010-2016 ^b	62.1 ^f	62.9 ^f	58.7	63.6 ^f	64.3	60.8	52.7	54.1	47.6
5-Year Period Survival (Percent) ^{cd}									
2016	61.3	62.3	57.6	62.3	63.1	58.9	53.5	54.4	50.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	16,104	12,984	3,120	12,834	10,354	2,480	2,510	1,970	540
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	53	54	47	55	56	49	44	46	36
Regional	24	22	33	24	22	33	26	23	36
Distant	19	20	17	18	18	16	27	28	25
Unstaged/Unknown	4	4	3	4	4	3	2	2	2
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	79.1	75.5	88.4	81.7	77.8	91.1	68.6 ^g	67.8 ^g	-
Ages 45-54	60.9	60.8	61.1	62.7	62.1	64.6	52.8	54.3	48.2 ^g
Ages 55-64	61.0	61.3	59.6	62.2	62.6	60.5	52.7	52.7	52.6
Ages 65-74	59.1	60.4	52.9	59.9	60.9	54.8	48.9	51.2	39.4 ^g
Ages 75+	58.9	61.3	49.0	59.9	62.3	49.0	45.9 ^g	46.7 ^g	43.3 ^h
Ages <65	62.0	61.9	62.5	63.5	63.2	64.5	53.6	54.0	52.3
Ages 65+	58.9	60.7	51.3	59.8	61.4	52.7	48.2	50.1	41.4 ^g
Stage ^e :									
All Stages	60.6	61.3	57.6	61.7	62.3	59.2	51.7	52.6	48.7
Localized	77.7	78.8	72.8	78.2	78.9	74.5	70.9	73.3	61.2
Regional	45.4	44.3	48.3	46.2	45.4	48.5	40.6	37.5	47.9
Distant	33.8	33.3	36.1	33.6	32.9	36.4	33.0	33.1	33.0
Unstaged/Unknown	52.7	54.7	40.0 ^g	51.9	53.5	41.4 ^g	37.3 ^g	37.0 ^g	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^d SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^e Based on follow-up of patients into 2017.^f Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^g Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^h The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

- The standard error is between 5 and 10 percentage points.

- The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 13.14
Leukemia

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	14	-	-	-	-	-
1970-1973 ^a	-	-	-	22	-	-	-	-	-
1975-1977 ^b	34.2	33.0	35.6	34.6	33.5	35.8	33.4	30.4	36.7
1978-1980 ^b	36.0	35.0	37.4	36.7	35.7	38.1	28.2	27.3	29.3
1981-1983 ^b	37.3	36.9	37.8	38.1	37.7	38.5	33.9	33.4	34.3
1984-1986 ^b	40.5	40.1	41.1	41.6	41.3	42.0	32.7	31.5	34.1
1987-1989 ^b	42.9	44.0	41.3	43.9	45.5	41.8	35.0	32.7	37.8
1990-1992 ^b	45.2	44.6	46.0	46.5	46.3	46.8	35.7	30.5	41.3
1993-1995 ^b	47.6	48.5	46.4	48.7	49.6	47.5	41.3	41.6	40.9
1996-1998 ^b	48.4	48.7	48.1	49.8	49.8	49.9	38.6	39.0	38.0
1999-2001 ^b	51.0	52.0	49.7	52.1	53.1	50.8	43.9	45.1	42.5
2002-2004 ^b	58.3	58.4	58.1	59.1	59.4	58.8	53.9	54.5	53.1
2005-2009 ^b	62.7	64.0	60.9	63.9	64.9	62.4	56.0	59.7	51.2
2010-2016 ^b	66.4 ^e	67.6 ^e	64.8 ^e	67.3 ^e	68.3 ^e	65.9 ^e	62.5 ^e	64.2 ^e	60.7 ^e
5-Year Period Survival (Percent) ^{cd}									
2016	64.3	65.2	63.1	64.5	64.8	64.0	60.6	64.1	56.7
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	76.8	76.5	77.3	77.8	76.9	78.9	69.4	69.3	69.5
Ages 45-54	73.3	74.9	71.0	74.3	75.6	72.2	66.9	69.6	63.2
Ages 55-64	70.4	71.2	69.2	71.7	71.9	71.4	59.6	64.2	53.1
Ages 65-74	62.1	62.3	61.8	62.5	62.2	63.0	57.1	59.8	53.4
Ages 75+	43.0	42.8	43.1	43.5	42.9	44.3	35.9	40.3	32.5
Ages <65	73.8	74.1	73.3	74.8	74.7	74.9	65.6	67.6	63.1
Ages 65+	51.9	52.8	50.8	52.3	52.7	51.9	47.5	52.4	42.9

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.

Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^f The standard error is between 5 and 10 percentage points.^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 13.15
Lymphocytic Leukemia

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>Acute Lymphocytic Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	40.6	36.9	45.6	40.8	37.4	45.7	33.5 ^e	-	-
...									
1987-1989 ^a	54.4	53.7	55.2	55.0	54.8	55.3	44.7 ^e	42.0 ^e	47.1 ^e
1990-1992 ^a	58.0	54.5	63.1	57.7	54.9	62.0	57.1 ^e	50.4 ^e	63.3 ^e
1993-1995 ^a	60.2	57.8	63.5	59.8	57.8	62.6	53.2 ^e	45.9 ^e	63.8 ^e
1996-1998 ^a	65.5	64.4	66.9	66.4	64.3	69.1	55.6 ^e	59.1 ^e	50.2 ^e
1999-2001 ^a	63.5	63.4	63.7	64.8	65.2	64.3	56.6 ^e	50.3 ^e	63.0 ^e
2002-2004 ^a	67.3	66.2	68.8	67.6	66.6	69.0	64.5 ^e	59.4 ^e	69.7 ^e
2005-2009 ^a	69.9	69.0	71.2	70.8	69.3	72.8	62.6	67.6	53.0 ^e
2010-2016 ^a	72.1 ^d	72.6 ^d	71.6 ^d	71.9 ^d	72.9 ^d	70.8 ^d	66.4 ^d	64.0	69.1
5-Year Period Survival (Percent) ^{bc}									
2016	69.0	68.1	70.1	68.4	66.8	70.6	67.5	67.6	67.0
5-Year Relative Survival (Percent), 2010-2016 ^b									
Age at Diagnosis:									
Ages <45	80.7	79.4	82.4	80.6	78.9	83.0	77.1	76.0	78.6
Ages 45-54	39.0	37.7	40.8	37.2	36.9	38.0	34.9 ^e	-	-
Ages 55-64	31.5	32.5	30.5	32.3	33.0	31.4	22.1 ^e	28.2 ^e	13.7 ^e
Ages 65-74	24.1	19.3	28.6	24.1	18.0	30.0	-	-	-
Ages 75+	11.1	10.0	12.0	11.1	9.0	12.9	-	-	-
Ages <65	73.5	72.8	74.5	73.4	72.3	74.8	68.5	67.8	69.3
Ages 65+	18.3	15.5	20.7	18.5	14.4	22.4	12.8 ^e	-	11.6 ^e
<u>Chronic Lymphocytic Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	67.1	64.7	70.4	67.9	65.3	71.3	56.9 ^e	55.1 ^e	59.0 ^e
...									
1987-1989 ^a	72.7	72.6	72.7	73.8	74.0	73.5	58.1	55.5 ^e	61.5 ^e
1990-1992 ^a	74.1	71.8	77.3	75.3	73.2	78.4	52.2	43.4 ^e	60.9 ^e
1993-1995 ^a	77.2	77.1	77.3	78.4	78.2	78.6	63.3	64.0 ^e	62.1 ^e
1996-1998 ^a	75.6	74.0	77.7	76.7	75.3	78.6	58.1	51.5 ^e	66.0 ^e
1999-2001 ^a	78.7	78.2	79.4	79.5	79.0	80.5	66.8	65.5 ^e	67.1 ^e
2002-2004 ^a	84.0	83.1	85.1	84.4	83.6	85.6	77.0	74.2 ^e	80.7 ^e
2005-2009 ^a	86.3	86.3	86.4	86.6	86.6	86.8	84.3	85.7	81.8
2010-2016 ^a	88.6 ^d	88.6 ^d	88.8 ^d	89.0 ^d	88.6 ^d	89.6 ^d	81.2 ^d	83.2 ^d	78.5
5-Year Period Survival (Percent) ^{bc}									
2016	87.0	86.8	87.3	86.6	85.9	87.5	82.4	86.7	76.5
5-Year Relative Survival (Percent), 2010-2016 ^b									
Age at Diagnosis:									
Ages <45	93.7	92.3	95.8	94.5	93.6	95.4	87.8 ^e	84.5 ^e	-
Ages 45-54	94.0	94.1	93.7	94.5	94.3	94.8	85.6	88.3	80.3 ^e
Ages 55-64	92.7	92.1	93.8	93.0	92.1	94.8	84.9	86.4	82.5
Ages 65-74	88.6	87.0	91.4	88.6	86.4	92.3	82.7	84.5	79.3
Ages 75+	74.3	73.3	75.3	73.9	72.4	75.3	64.0	67.6 ^e	60.8 ^e
Ages <65	93.1	92.7	93.9	93.5	92.8	94.9	85.4	87.0	82.7
Ages 65+	81.4	80.8	82.2	81.1	80.0	82.5	74.9	79.1	70.2

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c Based on follow-up of patients into 2017.
Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^d The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 13.16
Myeloid Leukemia

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>Acute Myeloid Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	6.2	5.5	6.9	5.8	5.4	6.2	10.1	8.2	11.7
...									
1987-1989 ^a	11.5	9.2	14.1	11.3	9.7	13.2	9.2	4.4	15.7 ^e
1990-1992 ^a	13.8	12.6	15.2	13.5	12.2	15.0	13.5	12.9	13.9
1993-1995 ^a	16.1	15.0	17.3	15.3	14.2	16.6	21.5	20.6 ^e	22.0
1996-1998 ^a	17.0	15.9	18.4	15.7	14.5	17.2	22.1	25.2	18.2
1999-2001 ^a	19.2	18.8	19.7	18.7	17.6	19.9	19.3	24.8	14.2
2002-2004 ^a	23.4	20.9	26.4	23.2	20.8	26.0	25.3	26.5	24.0
2005-2009 ^a	25.5	25.0	26.2	24.9	24.3	25.6	25.5	22.3	28.1
2010-2016 ^a	29.8 ^d	28.9 ^d	30.9 ^d	29.3 ^d	28.0 ^d	30.8 ^d	30.5 ^d	29.3 ^d	31.6 ^d
5-Year Period Survival (Percent) ^{bc}									
2016	29.3	28.8	29.9	28.8	28.0	29.5	29.2	28.6	29.7
5-Year Relative Survival (Percent), 2010-2016 ^b									
Age at Diagnosis:									
Ages <45	61.5	60.4	62.7	63.2	61.8	64.6	53.8	51.1	56.1
Ages 45-54	45.3	44.4	46.4	46.6	45.5	47.9	36.4	35.8	37.2
Ages 55-64	30.4	28.1	33.5	31.5	28.5	35.6	19.1	21.2	16.2
Ages 65-74	14.8	14.5	15.3	15.5	15.5	15.5	9.5	4.5	14.1
Ages 75+	3.2	3.8	2.4	3.2	3.8	2.5	2.6	5.5	0.9
Ages <65	47.5	45.2	50.2	48.4	45.7	51.6	40.2	38.4	42.0
Ages 65+	8.2	8.8	7.6	8.5	9.2	7.7	6.0	4.7	7.1
<u>Chronic Myeloid Leukemia</u>									
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	21.8	19.3	25.1	20.5	18.4	23.4	27.7 ^e	21.6 ^e	35.5 ^e
...									
1987-1989 ^a	30.3	30.6	29.8	30.1	31.0	29.0	33.3 ^e	28.1 ^e	41.3 ^e
1990-1992 ^a	30.6	29.6	31.9	30.1	30.0	30.3	34.9 ^e	25.5 ^e	44.9 ^e
1993-1995 ^a	35.5	35.2	35.9	35.1	35.0	35.2	35.6 ^e	32.8 ^e	40.2 ^e
1996-1998 ^a	37.2	37.7	36.4	38.1	37.6	38.5	31.0	30.4 ^e	31.4 ^e
1999-2001 ^a	47.3	45.9	49.3	45.9	44.1	48.3	49.5 ^e	49.6 ^e	49.3 ^e
2002-2004 ^a	54.4	53.1	56.2	52.8	51.5	54.4	62.9 ^e	63.3 ^e	61.9 ^e
2005-2009 ^a	63.4	63.4	63.5	62.5	62.2	63.0	61.4	63.3 ^e	58.1 ^e
2010-2016 ^a	71.7 ^d	70.1 ^d	73.7 ^d	70.7 ^d	69.4 ^d	72.3 ^d	78.3 ^d	75.7 ^d	80.7 ^d
5-Year Period Survival (Percent) ^{bc}									
2016	70.5	69.1	72.6	69.1	67.5	71.5	73.6	71.6	75.7
5-Year Relative Survival (Percent), 2010-2016 ^b									
Age at Diagnosis:									
Ages <45	90.1	89.3	91.3	91.4	90.8	92.3	82.1	80.3	84.6
Ages 45-54	89.2	87.2	92.1	88.6	86.6	91.5	90.3	87.7	92.5
Ages 55-64	77.7	76.2	80.0	78.1	75.4	81.9	69.1	76.2 ^e	60.8 ^e
Ages 65-74	61.3	58.4	65.2	61.1	57.9	65.9	57.5 ^e	53.5 ^e	61.3 ^e
Ages 75+	36.7	33.6	39.3	36.7	34.0	38.9	35.4 ^e	34.6 ^f	35.1 ^e
Ages <65	85.8	84.5	87.6	86.0	84.4	88.4	80.8	81.5	79.7
Ages 65+	48.6	46.8	50.9	48.2	46.4	50.6	48.8	47.4 ^e	50.2 ^e

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c Based on follow-up of patients into 2017.
Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^d The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^e The standard error is between 5 and 10 percentage points.

^f The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 14.8
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	3.4	1.8	6.3	3.4	2.0	5.8	1.8	0.0	5.6
1978-1980 ^b	3.3	2.2	5.4	3.3	2.2	4.8	3.6	3.0	5.0
1981-1983 ^b	3.7	2.9	5.2	4.0	3.0	5.5	2.8	2.1	4.7
1984-1986 ^b	5.6	3.6	9.5	5.7	3.7	9.1	4.4	2.1	9.1
1987-1989 ^b	4.9	3.2	8.0	5.7	3.4	9.4	2.7	1.6	4.9
1990-1992 ^b	5.6	5.0	7.0	6.3	5.1	8.3	2.6	2.0	3.6
1993-1995 ^b	5.5	5.3	6.0	5.2	4.9	5.7	4.0	2.8	7.3
1996-1998 ^b	8.6	8.3	9.1	8.4	7.6	10.2	4.6	5.9	2.0
1999-2001 ^b	11.3	10.9	12.1	10.3	9.6	11.7	7.6	6.8	9.5
2002-2004 ^b	14.8	14.9	14.7	14.1	14.6	13.0	9.6	7.3	15.8
2005-2009 ^b	17.6	17.7	17.3	16.8	17.1	16.2	12.7	12.4	13.6
2010-2016 ^b	20.8 ^f	20.8 ^f	20.9 ^f	19.9 ^f	20.2 ^f	19.0 ^f	18.7 ^f	18.3	19.7 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	20.6	20.3	21.1	19.5	19.5	19.8	18.4	17.8	19.9
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	51,112	37,202	13,910	35,853	26,237	9,616	6,689	4,952	1,737
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	44	44	44	44	45	43	42	41	44
Regional	27	27	24	26	27	25	29	30	27
Distant	18	18	19	18	17	19	19	20	18
Unstaged/Unknown	11	10	12	11	11	13	9	9	10
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	41.6	39.0	46.2	49.3	47.7	51.9	26.4	24.2	30.1 ^g
Ages 45-54	21.3	19.7	27.5	20.5	18.9	26.7	17.3	15.1	23.6
Ages 55-64	21.9	21.2	24.7	21.4	21.0	23.1	17.6	15.8	24.2
Ages 65-74	18.5	17.9	19.8	16.7	16.3	17.4	17.1	17.2	16.9
Ages 75+	9.8	9.7	10.0	8.1	8.0	8.2	8.5	7.1	9.5
Ages <65	23.0	21.7	27.7	22.7	21.6	27.0	18.1	16.1	24.7
Ages 65+	14.9	14.9	14.7	13.1	13.3	12.6	14.8	15.1	14.0
Stage ^e :									
All Stages	19.6	19.3	20.5	18.7	18.6	18.9	17.1	15.9	20.5
Localized	34.2	33.8	35.1	32.5	32.4	32.9	30.0	28.1	34.9
Regional	12.0	11.6	13.4	12.0	11.6	13.3	10.5	9.9	12.2
Distant	2.5	2.1	3.5	2.7	2.2	3.7	2.3	2.0	3.4
Unstaged/Unknown	7.0	6.4	8.1	5.7	5.4	6.4	9.3	8.9	10.3

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 15.12
Cancer of the Lung and Bronchus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	8	7	11	5	5	6
1970-1973 ^a	-	-	-	10	9	14	7	6	10
1975-1977 ^b	12.2	11.0	15.3	12.2	11.0	15.5	11.2	10.5	13.8
1978-1980 ^b	12.8	11.3	16.3	12.9	11.5	16.2	11.7	9.7	17.8
1981-1983 ^b	13.1	11.5	16.4	13.3	11.7	16.6	11.4	10.2	14.9
1984-1986 ^b	12.8	11.2	16.0	13.0	11.2	16.3	11.1	10.3	12.8
1987-1989 ^b	13.0	11.9	14.9	13.2	12.0	15.3	10.9	10.8	11.1
1990-1992 ^b	13.6	12.1	15.9	14.0	12.5	16.2	10.5	9.3	12.7
1993-1995 ^b	14.3	12.5	16.9	14.5	12.6	17.1	12.8	11.2	15.7
1996-1998 ^b	14.6	12.9	16.8	14.8	13.1	17.0	12.3	10.6	15.1
1999-2001 ^b	15.3	13.1	17.9	15.5	13.3	18.1	12.7	10.8	15.4
2002-2004 ^b	16.1	14.2	18.4	16.5	14.4	18.9	13.3	12.7	14.1
2005-2009 ^b	18.4	15.8	21.2	18.8	16.2	21.6	15.5	13.3	18.0
2010-2016 ^b	21.8 ^f	18.3 ^f	25.5 ^f	21.9 ^f	18.5 ^f	25.5 ^f	20.4 ^f	16.9 ^f	24.1 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	21.7	18.1	25.7	21.8	18.1	25.7	19.5	16.2	23.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	262,454	137,025	125,429	211,444	109,049	102,395	30,626	16,646	13,980
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	17	15	19	18	16	20	14	12	16
Regional	22	22	22	22	22	22	22	21	23
Distant	57	59	54	56	58	54	61	63	58
Unstaged/Unknown	4	4	4	4	4	5	3	3	3
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	36.6	31.2	41.7	38.1	32.8	42.9	28.8	24.4	34.1
Ages 45-54	23.5	18.6	28.7	23.6	18.6	28.8	21.5	16.8	26.7
Ages 55-64	22.0	18.2	26.8	21.9	18.2	26.6	19.8	16.2	25.0
Ages 65-74	22.2	18.6	26.4	22.4	18.7	26.4	18.8	15.6	22.8
Ages 75+	15.8	13.1	18.3	16.0	13.3	18.5	12.3	9.2	14.9
Ages <65	23.1	18.8	28.2	23.1	18.8	28.0	20.7	16.7	26.0
Ages 65+	19.1	16.1	22.2	19.3	16.2	22.3	16.2	13.3	19.2
Stage ^e :									
All Stages	20.5	17.1	24.2	20.6	17.2	24.2	18.4	15.1	22.3
Localized	59.0	53.0	64.1	59.1	53.2	64.0	54.8	46.8	61.8
Regional	31.7	28.1	35.7	31.4	27.9	35.1	30.6	27.0	34.6
Distant	5.8	4.7	7.1	5.5	4.3	6.7	6.0	5.1	7.1
Unstaged/Unknown	8.3	7.7	9.0	7.5	6.7	8.3	9.1	8.4	9.7

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 15.13
Small Cell Cancer of the Lung and Bronchus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	3.6	3.1	4.8	3.7	3.1	4.9	3.7	3.8	3.6
1978-1980 ^a	4.2	3.2	6.5	4.3	3.3	6.4	3.1	2.4	5.0
1981-1983 ^a	4.5	3.5	6.2	4.6	3.6	6.1	5.3	4.1	8.2
1984-1986 ^a	4.5	3.5	6.2	4.7	3.6	6.4	3.5	2.2	5.6
1987-1989 ^a	5.0	3.9	6.6	5.1	3.8	6.8	4.0	3.3	5.1
1990-1992 ^a	5.4	4.5	6.4	5.4	4.5	6.5	4.2	3.9	4.4
1993-1995 ^a	6.4	5.1	7.8	6.2	5.0	7.6	6.7	4.0	10.4
1996-1998 ^a	5.8	5.3	6.5	6.0	5.5	6.6	3.6	2.6	4.5
1999-2001 ^a	5.7	4.8	6.7	5.6	4.4	6.9	5.2	6.0	4.2
2002-2004 ^a	6.5	4.7	8.2	6.5	4.4	8.5	5.3	5.3	5.1
2005-2009 ^a	6.8	5.2	8.5	6.7	5.1	8.4	6.7	4.5	8.9
2010-2016 ^a	7.0 ^e	5.7 ^e	8.2 ^e	7.0 ^e	5.7 ^e	8.2 ^e	7.5 ^e	7.1 ^e	7.8
5-Year Period Survival (Percent) ^{bc}									
2016	6.7	5.0	8.4	6.7	4.9	8.4	7.7	7.0	8.5
Stage Distribution (%) 2010-2016 ^{bd}									
All Stages									
Number of cases	33,251	16,684	16,567	28,703	14,145	14,558	3,033	1,549	1,484
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	4	4	4	4	3	4	4	4	4
Regional	20	18	22	20	18	22	19	17	21
Distant	75	77	72	75	77	72	75	77	74
Unstaged/Unknown	2	2	2	2	2	2	2	2	1
5-Year Relative Survival (Percent), 2010-2016 ^b									
Age at Diagnosis:									
Ages <45	13.3	9.6	17.2	14.0	10.9	17.3	10.6	-	-
Ages 45-54	9.7	7.0	12.1	9.4	6.4	12.0	12.1	11.6	12.8
Ages 55-64	7.8	5.7	10.0	7.8	5.6	10.0	8.0	5.9	10.1
Ages 65-74	6.2	5.5	7.0	6.2	5.3	7.1	7.1	7.9	6.2
Ages 75+	3.7	2.8	4.5	3.7	2.7	4.5	3.5	2.1	4.5
Ages <65	8.4	6.1	10.7	8.3	5.9	10.7	9.2	7.5	10.9
Ages 65+	5.2	4.5	6.0	5.2	4.3	6.0	5.8	6.1	5.5
Stage ^d :									
All Stages	6.5	5.1	7.9	6.5	5.0	7.9	7.5	6.8	8.2
Localized	27.2	25.5	28.3	27.2	25.4	28.4	34.9 ^f	37.4 ^f	32.1 ^f
Regional	16.4	14.8	17.7	16.5	14.7	18.0	17.5	16.1	18.7
Distant	2.9	2.0	3.8	2.8	1.9	3.7	3.8	3.3	4.2
Unstaged/Unknown	8.1	5.7	10.2	8.0	4.2	11.0	3.4	6.6 ^f	-

Note: Small Cell Cancer of the Lung and Bronchus includes histologies 8002, 8041-8045.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^c Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^d Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^e The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 15.14
Non-Small Cell Cancer of the Lung and Bronchus (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1975-1977 ^a	16.4	14.8	21.1	16.7	15.0	21.5	13.4	12.4	17.7
1978-1980 ^a	16.7	14.8	21.4	17.0	15.2	21.5	14.2	11.6	22.8
1981-1983 ^a	17.1	15.0	21.7	17.5	15.4	22.1	13.9	12.2	19.2
1984-1986 ^a	16.6	14.4	21.0	17.0	14.7	21.5	13.1	11.9	16.4
1987-1989 ^a	16.8	15.2	19.8	17.3	15.5	20.5	13.2	12.9	13.9
1990-1992 ^a	17.7	15.5	21.1	18.3	16.2	21.7	12.8	11.1	16.2
1993-1995 ^a	18.7	16.1	22.5	19.3	16.5	23.3	15.1	13.3	18.5
1996-1998 ^a	19.4	16.7	22.9	19.9	17.1	23.5	15.3	12.7	19.5
1999-2001 ^a	20.0	16.9	24.1	20.7	17.5	24.7	14.8	12.0	18.9
2002-2004 ^a	19.6	17.0	22.8	20.4	17.7	23.7	15.0	13.9	16.6
2005-2009 ^a	22.2	18.9	26.0	23.1	19.7	26.8	17.4	14.8	20.6
2010-2016 ^a	26.5 ^e	22.1 ^e	31.2 ^e	27.0 ^e	22.5 ^e	31.8 ^e	23.4 ^e	19.0 ^e	28.1 ^e
5-Year Period Survival (Percent) ^{bc}									
2016	26.3	21.8	31.2	26.8	22.1	31.7	22.4	18.4	27.1
Stage Distribution (%) 2010-2016 ^{bd}									
All Stages									
Number of cases	199,070	104,884	94,186	157,707	82,267	75,440	24,448	13,379	11,069
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	20	17	23	21	18	24	16	14	18
Regional	24	24	23	24	25	24	24	23	24
Distant	54	57	52	53	55	51	59	62	56
Unstaged/Unknown	2	2	2	2	2	2	2	2	2
5-Year Relative Survival (Percent), 2010-2016 ^b									
Age at Diagnosis:									
Ages <45	38.7	33.3	43.7	40.6	35.0	45.6	30.1	26.1	34.8
Ages 45-54	26.4	20.8	32.3	27.0	21.2	33.0	23.0	17.5	28.7
Ages 55-64	25.7	21.2	31.4	26.0	21.6	31.6	22.1	18.2	27.8
Ages 65-74	26.7	22.2	31.7	27.2	22.7	32.2	21.6	17.5	26.7
Ages 75+	20.8	17.0	24.5	21.3	17.4	24.9	15.8	11.7	19.7
Ages <65	26.5	21.6	32.4	27.0	22.0	32.8	22.7	18.4	28.4
Ages 65+	24.0	19.9	28.3	24.4	20.3	28.7	19.4	15.4	23.8
Stage ^d :									
All Stages	24.9	20.6	29.7	25.3	21.0	30.1	21.1	17.0	26.0
Localized	63.1	56.7	68.4	63.2	57.0	68.4	58.1	49.1	65.9
Regional	35.4	30.9	40.6	35.2	30.8	40.1	33.3	29.1	38.0
Distant	6.9	5.6	8.6	6.6	5.2	8.2	6.6	5.6	8.0
Unstaged/Unknown	14.8	14.2	15.5	13.7	12.9	14.6	11.5	9.4	13.5

Note: Non-Small Cell Cancer of the Lung and Bronchus includes histologies 8003-8004, 8012-8015, 8021-8022, 8030-8035, 8046, 8050-8052, 8070-8076, 8078, 8082-8084, 8090, 8094, 8120, 8123, 8140-8141, 8143-8145, 8147, 8190, 8200-8201, 8211, 8240-8241, 8243-8246, 8249-8255, 8260, 8290, 8310, 8320, 8323, 8333, 8401, 8430, 8440, 8470-8471, 8480-8481, 8490, 8503, 8507, 8525, 8550, 8560, 8562, 8570-8572, 8574-8576.

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^c Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^d Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^e The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^f The standard error is between 5 and 10 percentage points.

^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 16.8
Melanoma of the Skin (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	60	51	68	-	-	-
1970-1973 ^a	-	-	-	68	62	75	-	-	-
1975-1977 ^b	81.9	77.5	86.3	82.1	77.9	86.3	56.7 ^g	-	-
1978-1980 ^b	82.7	77.7	87.8	82.9	77.8	87.9	59.8 ^h	-	-
1981-1983 ^b	82.8	78.4	87.3	82.8	78.5	87.2	61.9 ^g	-	-
1984-1986 ^b	86.6	82.6	91.0	86.5	82.3	91.0	72.3 ^h	-	-
1987-1989 ^b	88.1	84.9	91.5	88.0	84.9	91.3	78.6 ^g	-	89.5 ^g
1990-1992 ^b	89.3	87.0	91.8	89.4	87.2	91.8	59.7 ^g	-	-
1993-1995 ^b	89.7	87.3	92.6	89.6	87.2	92.7	69.5 ^g	66.6 ^g	-
1996-1998 ^b	91.0	89.5	92.7	90.9	89.4	92.7	73.9 ^g	68.0 ^h	78.6 ^g
1999-2001 ^b	92.2	90.2	94.6	92.3	90.3	94.6	73.9 ^g	70.9 ^g	76.1 ^g
2002-2004 ^b	93.2	91.1	95.5	93.2	91.1	95.7	72.2 ^g	-	70.9 ^g
2005-2009 ^b	93.3	91.7	95.3	93.4	91.8	95.4	73.0	61.1 ^g	80.2 ^g
2010-2016 ^b	95.0 ^f	93.4 ^f	96.8 ^f	94.9 ^f	93.3 ^f	96.9 ^f	69.5 ^g	65.2 ^g	72.1 ^g
5-Year Period Survival (Percent) ^{cd}									
2016	93.3	91.8	95.3	92.7	91.0	94.9	76.2	67.5	82.9
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	108,462	61,289	47,173	100,723	57,211	43,512	485	212	273
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	83	81	85	83	81	85	54	50	58
Regional	9	10	7	9	10	8	25	29	22
Distant	4	5	3	4	5	3	16	16	15
Unstaged/Unknown	4	4	4	4	4	4	5	6	4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	95.1	92.2	97.0	94.9	91.9	96.9	87.2	81.9 ^g	89.2 ^g
Ages 45-54	93.7	91.4	96.3	93.5	91.0	96.2	58.8 ^g	43.7 ^h	72.9 ^g
Ages 55-64	92.8	91.2	95.3	92.4	90.8	95.0	69.8	59.3 ^g	80.8 ^g
Ages 65-74	93.4	92.5	95.1	92.9	91.9	94.8	68.6 ^g	64.3 ^g	71.2 ^g
Ages 75+	87.9	87.7	88.3	86.7	86.2	87.5	33.3 ^h	34.1 ^h	30.0 ^h
Ages <65	93.8	91.5	96.2	93.5	91.1	96.1	72.9	60.0 ^g	82.6
Ages 65+	91.1	90.6	91.9	90.2	89.5	91.4	55.9 ^g	55.8 ^g	54.5 ^g
Stage ^e :									
All Stages	92.7	91.1	94.8	92.2	90.4	94.5	66.7	59.5	72.1
Localized	99.0	98.7	99.4	98.6	98.1	99.2	85.2	82.4 ^g	86.6
Regional	66.2	63.5	70.7	66.5	63.8	71.1	49.4 ^g	44.9 ^g	53.3 ^g
Distant	27.3	26.2	29.7	27.3	26.3	29.6	26.7 ^g	-	35.8 ^g
Unstaged/Unknown	87.2	85.6	88.8	85.4	83.6	87.3	-	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 17.4
Mesothelioma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	-	-	-	-	-	-
1970-1973 ^a	-	-	-	-	-	-	-	-	-
1975-1977 ^b	9.7	3.0	26.7	10.4	3.3	27.4 ^f	-	-	-
1978-1980 ^b	6.0	5.5	8.1	5.9	5.2	8.7	-	-	-
1981-1983 ^b	7.7	5.3	15.1	8.1	5.4	16.2	-	-	-
1984-1986 ^b	6.6	4.3	13.9	6.1	3.7	14.1	-	-	-
1987-1989 ^b	6.3	4.6	12.2	6.4	4.8	12.1	4.8	-	-
1990-1992 ^b	7.7	4.2	20.6	7.4	4.0	20.1	10.2 ^f	8.5 ^f	-
1993-1995 ^b	6.5	3.2	18.7	5.9	2.8	18.0	9.0	8.0 ^f	-
1996-1998 ^b	9.8	8.2	15.2	9.8	8.0	16.2	11.4 ^f	-	-
1999-2001 ^b	7.6	5.3	15.9	6.7	5.0	13.0	-	-	-
2002-2004 ^b	6.6	4.9	11.6	6.1	4.5	10.9	7.9 ^f	-	-
2005-2009 ^b	10.1	7.3	18.4	10.6	7.4	20.7	6.7	5.6 ^f	-
2010-2016 ^b	10.7	8.3 ^e	18.6	10.1	7.9 ^e	17.4	13.7 ^f	0.0	-
5-Year Period Survival (Percent) ^{cd}									
2016	12.2	9.2	20.8	11.6	8.6	20.6	17.3	16.2	18.5
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	42.2 ^f	31.8 ^f	52.8 ^f	42.7 ^f	33.1 ^f	53.5 ^f	-	-	-
Ages 45-54	23.3	17.6	31.8 ^f	21.1	16.2	29.0 ^f	32.0 ^f	-	-
Ages 55-64	14.3	12.7	18.3	13.6	12.1	17.6	18.1 ^f	14.6 ^f	-
Ages 65-74	8.9	6.9	16.2	8.8	6.8	16.2	9.1	9.7	-
Ages 75+	4.6	3.9	7.0	4.3	3.4	7.3	4.3	3.0	-
Ages <65	19.9	15.6	28.0	18.8	15.0	26.3	25.4 ^f	15.7 ^f	34.2 ^f
Ages 65+	6.4	5.2	10.8	6.2	4.9	10.9	7.0	6.6	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.

Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^f The standard error is between 5 and 10 percentage points.^g The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 18.8
Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	12	13	10	-	-	-
1970-1973 ^a	-	-	-	19	20	17	-	-	-
1975-1977 ^b	24.5	23.9	25.2	24.0	23.6	24.6	29.3	28.9	29.5
1978-1980 ^b	25.9	24.4	27.4	24.8	24.1	25.4	32.5	27.4	37.5
1981-1983 ^b	27.6	25.8	29.5	27.3	25.6	29.1	28.9	29.6	27.9
1984-1986 ^b	27.3	27.7	26.9	26.1	25.9	26.3	31.8	33.3	30.3
1987-1989 ^b	27.2	28.9	25.4	26.8	29.1	24.4	29.9	29.6	30.1
1990-1992 ^b	29.3	30.5	27.9	28.4	29.6	26.9	34.4	38.0	30.9
1993-1995 ^b	31.7	32.3	31.0	30.6	31.5	29.5	35.4	34.9	35.7
1996-1998 ^b	32.5	34.5	30.3	32.2	34.4	29.8	31.7	33.2	30.6
1999-2001 ^b	34.6	37.2	31.6	34.5	37.2	31.3	34.3	37.2	31.7
2002-2004 ^b	42.6	43.6	41.5	43.4	44.8	41.7	41.1	41.6	40.7
2005-2009 ^b	48.9	49.3	48.4	48.3	49.8	46.5	51.1	47.6	54.2
2010-2016 ^b	55.1 ^f	55.9 ^f	54.2 ^f	54.5 ^f	55.5 ^f	53.1 ^f	56.8 ^f	57.1 ^f	56.6 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	55.1	55.4	54.8	53.7	54.1	53.2	57.9	57.9	57.9
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	35,428	19,572	15,856	25,440	14,567	10,873	7,263	3,532	3,731
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	5	5	4	5	5	4	4	4	3
Regional	0	0	0	0	0	0	0	0	0
Distant	95	95	96	95	95	96	96	96	97
Unstaged/Unknown	0	0	0	0	0	0	0	0	0
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	76.8	76.0	77.9	78.4	78.1	78.8	72.2	69.8	74.7
Ages 45-54	67.5	65.2	70.5	66.5	64.3	69.8	69.1	66.6	71.4
Ages 55-64	62.1	60.6	64.0	62.4	61.3	64.0	60.7	58.4	63.1
Ages 65-74	54.9	54.3	55.8	54.4	53.4	55.8	55.7	56.6	54.8
Ages 75+	35.0	35.4	34.5	33.8	34.9	32.6	38.1	35.5	39.8
Ages <65	65.1	63.5	67.3	65.1	63.7	67.0	64.7	62.4	67.1
Ages 65+	45.4	45.8	45.0	44.3	44.8	43.7	48.3	48.9	47.8
Stage ^e :									
All Stages	53.9	53.7	54.1	52.7	52.8	52.5	56.8	56.3	57.3
Localized	74.8	76.2	72.6	75.8	77.3	73.1	67.8	69.3 ^g	66.0 ^g
Regional	-	-	-	-	-	-	-	-	-
Distant	52.9	52.5	53.3	51.4	51.3	51.5	56.4	55.8	57.0
Unstaged/Unknown	-	-	-	-	-	-	-	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.

Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 19.8
Non-Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	31	31	31	-	-	-
1970-1973 ^a	-	-	-	41	39	43	-	-	-
1975-1977 ^b	46.5	45.5	47.5	46.8	46.3	47.3	48.6	42.6	55.3 ^g
1978-1980 ^b	47.9	46.1	49.8	47.9	46.3	49.6	51.1	46.9	56.7
1981-1983 ^b	50.6	50.3	50.9	50.7	50.5	51.0	49.5	49.2	49.8
1984-1986 ^b	51.6	50.0	53.3	52.0	50.6	53.6	46.8	44.5	49.9
1987-1989 ^b	50.9	47.6	54.9	51.4	48.2	55.2	45.7	41.3	51.0
1990-1992 ^b	50.7	46.7	55.7	51.5	47.6	56.4	42.2	38.4	47.6
1993-1995 ^b	52.6	48.8	57.5	53.3	49.8	57.7	42.6	35.9	55.1
1996-1998 ^b	58.8	57.0	61.0	59.4	57.6	61.5	54.8	53.2	57.3
1999-2001 ^b	64.0	61.5	67.0	65.0	62.9	67.5	55.7	49.1	63.7
2002-2004 ^b	69.8	68.6	71.2	71.0	70.1	72.1	63.7	61.3	66.6
2005-2009 ^b	72.1	71.0	73.4	73.3	72.4	74.5	62.9	58.3	68.0
2010-2016 ^b	75.1 ^f	74.3 ^f	76.1 ^f	75.9 ^f	75.1 ^f	76.9 ^f	71.5 ^f	69.0 ^f	74.4 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	73.1	71.9	74.5	73.5	72.2	75.1	69.2	67.6	70.8
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	99,037	54,394	44,643	81,022	44,677	36,345	8,357	4,473	3,884
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	27	26	28	27	26	28	28	25	31
Regional	15	15	15	15	15	15	15	15	15
Distant	50	52	48	51	52	49	51	54	48
Unstaged/Unknown	8	7	8	7	7	8	6	6	7
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	84.7	82.7	87.8	85.9	83.8	89.2	75.8	73.5	79.2
Ages 45-54	81.8	78.4	86.7	83.4	80.3	88.0	69.8	64.3	77.0
Ages 55-64	77.6	75.1	81.1	78.7	76.2	82.0	69.7	65.0	75.7
Ages 65-74	73.3	71.6	75.3	73.9	71.9	76.3	67.3	65.5	68.5
Ages 75+	56.1	55.2	56.9	56.6	55.4	57.7	52.0	50.3	52.7
Ages <65	80.6	78.0	84.3	81.7	79.3	85.3	71.8	67.9	77.2
Ages 65+	64.6	63.9	65.4	65.1	64.1	66.2	60.9	60.4	61.1
Stage ^e :									
All Stages	72.7	71.5	74.2	73.1	71.9	74.6	68.4	66.0	71.2
Localized	84.7	84.0	85.5	85.1	84.4	85.8	82.4	77.8	86.7
Regional	75.5	75.9	75.1	76.0	76.3	75.5	70.7	70.9	70.3
Distant	65.8	64.4	67.5	66.7	65.3	68.5	60.3	59.3	61.6
Unstaged/Unknown	70.0	67.7	72.5	67.7	65.3	70.3	66.6	63.1	69.7

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 20.10
Cancer of the Oral Cavity and Pharynx (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	45	-	-	-	-	-
1970-1973 ^a	-	-	-	43	-	-	-	-	-
1975-1977 ^b	52.5	51.5	54.7	54.0	53.7	54.7	36.0	29.7	49.0
1978-1980 ^b	53.3	51.8	56.5	55.4	54.5	57.4	34.9	29.8	45.8
1981-1983 ^b	51.7	50.1	55.1	54.0	52.9	56.5	30.9	25.4	45.6
1984-1986 ^b	54.1	51.6	59.0	56.3	54.8	59.4	35.0	29.5	49.1
1987-1989 ^b	53.6	51.1	58.8	56.0	54.1	59.8	34.0	30.0	44.0
1990-1992 ^b	55.4	53.1	60.1	57.9	56.4	61.0	33.1	28.4	46.0
1993-1995 ^b	57.6	56.2	60.5	60.0	59.4	61.3	38.0	33.1	50.5
1996-1998 ^b	57.8	56.2	61.0	59.9	59.1	61.5	36.3	31.3	49.2
1999-2001 ^b	60.3	59.2	62.6	62.3	62.1	62.7	44.6	39.4	57.3
2002-2004 ^b	63.9	63.1	65.8	65.7	65.7	65.7	48.4	43.1	58.8
2005-2009 ^b	65.9	65.4	67.2	67.7	67.5	68.2	44.8	42.2	50.4
2010-2016 ^b	69.2 ^f	68.5 ^f	71.1 ^f	71.2 ^f	70.9 ^f	72.2 ^f	51.3 ^f	49.6 ^f	54.9
5-Year Period Survival (Percent) ^{cd}									
2016	66.5	66.2	67.2	67.6	67.6	67.7	50.1	49.7	50.6
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	59,271	42,757	16,514	48,501	35,464	13,037	5,199	3,615	1,584
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	29	24	41	29	25	43	19	15	30
Regional	48	52	38	49	53	38	48	51	39
Distant	19	20	16	18	19	14	29	31	26
Unstaged/Unknown	4	4	5	4	4	5	4	3	4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	80.6	78.1	84.7	81.9	79.5	85.8	73.4	70.5	77.1
Ages 45-54	71.2	70.6	73.2	73.9	73.5	75.2	50.7	48.8	55.7
Ages 55-64	67.8	67.0	70.5	69.7	68.9	72.5	48.5	47.7	50.5
Ages 65-74	63.3	61.8	67.5	64.6	63.5	67.8	43.8	39.4	53.9
Ages 75+	51.9	52.1	51.6	52.8	53.4	52.0	34.1	36.0	32.2
Ages <65	70.7	69.5	74.4	72.6	71.5	75.9	52.8	50.7	58.0
Ages 65+	58.7	58.4	59.4	59.8	59.9	59.7	41.0	38.7	44.6
Stage ^e :									
All Stages	66.2	65.6	67.7	67.6	67.3	68.3	49.5	47.6	53.8
Localized	85.1	84.3	86.1	85.3	85.1	85.7	77.3	72.6	81.6
Regional	66.8	68.1	62.2	68.1	69.6	62.6	51.7	52.2	50.2
Distant	40.1	40.5	38.7	41.1	41.8	38.4	29.3	28.9	30.4
Unstaged/Unknown	54.0	54.0	53.4	51.5	51.6	51.0	39.2	40.9 ^g	36.1 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 21.8
Cancer of the Ovary(Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<65	65+	All	<65	65+	All	<65	65+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	32	-	-	32	-	-
1970-1973 ^a	-	-	-	36	-	-	32	-	-
1975-1977 ^b	35.9	44.1	21.3	35.2	43.5	21.0	41.6	48.6	24.9 ^g
1978-1980 ^b	37.6	47.3	21.9	36.8	46.4	22.1	38.8	49.2	12.8
1981-1983 ^b	38.9	50.3	23.1	38.5	50.2	23.1	37.9	46.0	22.6
1984-1986 ^b	38.5	49.4	24.2	37.6	48.5	23.9	39.2	51.9	21.2
1987-1989 ^b	38.2	51.1	23.6	38.2	51.3	23.9	33.9	47.2	17.1
1990-1992 ^b	40.6	55.6	24.1	40.5	56.2	24.1	35.7	49.4	16.8
1993-1995 ^b	41.6	55.9	26.6	40.7	55.5	26.1	41.3	54.8	26.4
1996-1998 ^b	43.8	57.1	28.2	43.2	56.5	28.4	39.2	53.3	20.4
1999-2001 ^b	43.9	56.0	28.9	43.6	56.6	28.8	35.7	44.2	21.9
2002-2004 ^b	43.9	57.0	27.0	43.3	56.8	27.2	36.9	46.8	20.8
2005-2009 ^b	45.8	59.2	27.6	45.5	59.4	28.1	37.1	46.1	22.2
2010-2016 ^b	49.4 ^f	61.4 ^f	32.8 ^f	49.1 ^f	62.1 ^f	33.0 ^f	42.2	52.1	24.2
5-Year Period Survival (Percent) ^{cd}									
2016	49.3	61.0	33.3	48.9	61.6	33.3	42.3	51.7	24.5
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	34,175	19,504	14,671	27,575	15,102	12,473	3,109	1,938	1,171
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	16	22	8	15	21	8	15	20	7
Regional	21	25	15	21	25	15	16	19	12
Distant	58	50	68	59	50	68	63	57	72
Unstaged/Unknown	5	3	8	5	3	8	6	5	9
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	77.1	-	-	78.1	-	-	72.6	-	-
Ages 45-54	61.1	-	-	61.6	-	-	51.8	-	-
Ages 55-64	51.4	-	-	52.5	-	-	38.3	-	-
Ages 65-74	41.1	-	-	42.0	-	-	26.0	-	-
Ages 75+	23.2	-	-	23.0	-	-	17.7	-	-
Ages <65	60.5	-	-	61.1	-	-	51.3	-	-
Ages 65+	32.4	-	-	32.7	-	-	22.2	-	-
Stage ^e :									
All Stages	48.6	60.5	32.4	48.4	61.1	32.7	40.8	51.3	22.2
Localized	92.6	93.9	87.9	93.3	94.8	88.1	89.5	91.2	80.1 ^g
Regional	74.8	80.8	61.6	75.5	82.0	62.5	64.3	71.3	43.1 ^g
Distant	30.2	37.9	22.6	30.4	38.6	22.7	23.6	29.7	15.1
Unstaged/Unknown	25.5	52.4	10.5	23.4	51.1	10.2	30.7	57.2 ^g	6.5

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 22.8
Cancer of the Pancreas (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	1	1	2	1	0	3
1970-1973 ^a	-	-	-	2	2	2	2	0	3
1975-1977 ^b	2.5	2.6	2.2	2.5	2.7	2.3	2.3	2.5	1.9
1978-1980 ^b	2.9	2.7	3.0	2.5	2.6	2.5	5.8	4.5	7.0
1981-1983 ^b	2.7	2.4	3.1	2.5	2.1	3.0	3.6	3.7	3.2
1984-1986 ^b	2.9	2.3	3.5	2.6	2.1	3.1	4.7	3.9	5.3
1987-1989 ^b	3.5	3.3	3.7	3.2	3.0	3.3	5.5	5.1	5.8
1990-1992 ^b	4.3	4.1	4.5	4.4	4.2	4.5	3.6	3.2	4.0
1993-1995 ^b	4.0	3.7	4.3	3.9	3.6	4.2	3.7	3.6	3.7
1996-1998 ^b	4.3	4.6	4.1	4.1	4.6	3.6	3.4	3.1	3.5
1999-2001 ^b	5.1	5.2	5.0	5.0	5.5	4.5	5.6	3.7	7.4
2002-2004 ^b	5.6	5.3	5.9	5.7	5.6	5.8	4.5	3.0	5.7
2005-2009 ^b	7.7	7.8	7.6	7.8	7.8	7.7	6.4	6.8	6.1
2010-2016 ^b	10.5 ^f	10.7 ^f	10.2 ^f	10.4 ^f	10.7 ^f	10.2 ^f	10.3 ^f	10.5 ^f	10.1 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	11.0	11.0	11.0	10.8	10.9	10.7	10.6	9.8	11.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	65,128	33,078	32,050	51,197	26,465	24,732	8,087	3,741	4,346
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	11	10	12	11	10	12	11	9	12
Regional	30	29	30	30	30	30	28	26	29
Distant	52	55	50	52	54	50	56	59	53
Unstaged/Unknown	7	6	8	7	6	8	6	5	7
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	40.6	32.6	48.9	41.3	34.2	49.1	37.7	23.3	49.0
Ages 45-54	17.1	15.2	19.6	16.7	14.6	19.8	16.2	15.5	17.1
Ages 55-64	11.3	10.6	12.3	11.3	10.8	12.1	9.9	8.9	11.2
Ages 65-74	9.1	9.2	9.0	9.1	9.2	9.0	8.0	7.4	8.5
Ages 75+	4.7	5.2	4.4	4.8	5.3	4.4	4.5	2.7	5.1
Ages <65	15.2	13.4	17.6	15.0	13.4	17.3	13.9	11.7	16.4
Ages 65+	6.8	7.4	6.3	6.8	7.4	6.3	6.4	5.8	6.7
Stage ^e :									
All Stages	10.0	10.0	10.0	9.8	9.9	9.8	10.1	9.2	10.8
Localized	39.4	40.9	38.1	39.2	41.2	37.3	36.0	33.5	37.5
Regional	13.3	14.0	12.6	13.2	13.7	12.5	14.5	15.3	13.8
Distant	2.9	2.9	3.0	2.9	2.9	3.0	2.9	2.8	2.9
Unstaged/Unknown	6.1	6.6	5.6	5.4	6.2	4.5	11.1	9.2	12.5

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.

Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 23.8
Cancer of the Prostate (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Males			White Males			Black Males		
	All	<65	65+	All	<65	65+	All	<65	65+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	50	-	-	35	-	-
1970-1973 ^a	-	-	-	63	-	-	55	-	-
1975-1977 ^b	67.8	73.4	66.1	68.5	75.2	66.6	60.7	62.0	60.1
1978-1980 ^b	70.1	75.2	68.6	71.2	76.7	69.6	62.1	65.0	60.6
1981-1983 ^b	72.0	76.0	70.9	73.1	77.6	71.9	62.8	65.0	61.9
1984-1986 ^b	75.1	77.2	74.5	76.3	78.9	75.6	65.6	67.2	64.9
1987-1989 ^b	82.8	83.2	82.7	84.4	84.7	84.3	71.2	72.8	70.7
1990-1992 ^b	92.9	92.9	92.9	94.1	94.0	94.1	84.5	86.8	83.6
1993-1995 ^b	95.2	95.9	94.9	96.0	96.5	95.7	91.9	93.4	91.0
1996-1998 ^b	97.3	98.5	96.7	97.9	98.9	97.3	95.0	96.7	93.7
1999-2001 ^b	99.3	99.1	99.3	99.7	99.5	99.6	97.4	98.1	96.4
2002-2004 ^b	99.6	99.5	99.7	99.8	99.6	99.7	98.0	99.2	96.3
2005-2009 ^b	99.5	99.6	99.4	99.8	99.9	99.6	98.3	98.6	97.8
2010-2016 ^b	98.3 ^f	99.0 ^f	97.7 ^f	98.7 ^f	99.4 ^f	98.1 ^f	96.3 ^f	97.5 ^f	94.4 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	97.3	97.9	96.8	97.2	98.0	96.6	95.9	97.2	94.2
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	332,075	145,886	186,189	248,870	104,945	143,925	53,305	29,514	23,791
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	76	77	75	76	77	76	78	79	78
Regional	13	16	11	14	17	12	11	14	8
Distant	6	4	8	6	4	8	7	5	9
Unstaged/Unknown	5	3	6	4	2	5	4	3	5
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	96.1	-	-	95.0	-	-	97.7	-	-
Ages 45-54	97.3	-	-	96.9	-	-	97.9	-	-
Ages 55-64	98.5	-	-	98.7	-	-	97.2	-	-
Ages 65-74	100.0	-	-	100.0	-	-	97.6	-	-
Ages 75+	90.9	-	-	90.4	-	-	84.7	-	-
Ages <65	98.2	-	-	98.3	-	-	97.5	-	-
Ages 65+	97.5	-	-	97.4	-	-	94.5	-	-
Stage ^e :									
All Stages	97.8	98.2	97.5	97.8	98.3	97.4	96.2	97.5	94.5
Localized	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Regional	100.0	99.7	100.0	100.0	99.6	100.0	100.0	100.0	99.7
Distant	30.2	33.5	28.8	29.5	32.7	28.3	29.9	33.6	27.0
Unstaged/Unknown	83.3	92.4	79.8	76.8	89.7	72.5	74.4	86.9	66.7

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.⁻ Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 24.8
Cancer of the Stomach (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	11	10	13	8	5	14
1970-1973 ^a	-	-	-	13	12	14	13	15	10
1975-1977 ^b	15.2	14.4	16.5	14.1	13.1	15.8	16.1	16.1	16.1
1978-1980 ^b	16.0	14.2	18.9	15.3	13.6	18.2	16.4	15.6	18.0
1981-1983 ^b	17.2	16.3	18.7	16.2	15.4	17.5	16.5	16.2	17.1
1984-1986 ^b	17.6	15.6	20.9	16.8	14.4	20.9	19.1	16.9	22.1
1987-1989 ^b	19.7	16.9	24.3	18.3	15.5	23.1	18.8	16.6	22.5
1990-1992 ^b	20.9	18.1	25.5	18.8	16.1	23.2	22.7	22.0	23.7
1993-1995 ^b	21.1	20.1	22.6	20.0	18.9	21.9	19.3	17.5	21.9
1996-1998 ^b	22.3	21.1	24.2	20.3	18.7	23.1	22.6	20.4	25.3
1999-2001 ^b	24.1	23.4	25.2	22.3	21.0	24.2	23.1	24.9	20.6
2002-2004 ^b	27.5	25.1	31.0	26.0	24.0	29.5	29.1	24.8	34.1
2005-2009 ^b	30.1	28.1	33.2	29.0	27.7	31.4	29.3	24.1	36.4
2010-2016 ^b	32.6 ^f	30.2 ^f	36.4 ^f	31.8 ^f	29.5 ^f	35.8 ^f	33.9 ^f	27.2 ^f	42.1 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	32.2	29.1	36.9	30.8	27.5	36.3	32.6	27.5	39.3
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	37,620	22,781	14,839	26,255	16,402	9,853	5,137	2,878	2,259
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	28	25	33	28	24	33	29	25	35
Regional	26	28	23	26	28	22	25	26	24
Distant	36	39	33	37	40	33	36	41	31
Unstaged/Unknown	10	8	12	9	8	12	9	8	11
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	35.1	31.2	39.5	34.5	30.5	39.2	36.6	32.5	40.9
Ages 45-54	36.1	31.5	43.5	34.8	30.2	43.1	37.1	30.1	47.1
Ages 55-64	34.3	30.2	42.5	33.1	29.4	41.1	34.0	26.0	47.4
Ages 65-74	35.2	31.2	42.6	33.4	29.7	40.9	33.6	26.8	44.1
Ages 75+	24.6	23.4	26.0	23.8	22.2	25.8	23.0	19.0	25.8
Ages <65	35.0	30.7	42.2	33.8	29.7	41.3	35.4	28.1	46.4
Ages 65+	29.6	27.4	32.7	28.4	26.0	32.0	28.3	23.6	33.3
Stage ^e :									
All Stages	32.0	28.9	36.7	30.8	27.7	35.9	31.9	26.1	39.4
Localized	69.5	65.1	74.5	68.2	64.0	73.2	66.3	57.4	74.6
Regional	32.0	31.7	32.6	30.2	30.2	30.3	34.0	32.8	35.5
Distant	5.5	5.6	5.2	5.3	5.7	4.5	5.4	4.0	7.5
Unstaged/Unknown	23.4	19.8	27.5	23.5	18.8	29.1	23.3	16.5	29.3

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.

Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 25.8
Cancer of the Testis (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Males			White Males			Black Males		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	63	-	-	-	-	-
1970-1973 ^a	-	-	-	72	-	-	-	-	-
1975-1977 ^b	82.7	83.3	77.7	82.6	83.3	77.4	-	-	-
1978-1980 ^b	88.8	89.5	82.2	89.2	89.8	83.1	73.1 ^g	78.0 ^g	-
1981-1983 ^b	92.0	92.5	85.5	92.2	92.8	86.2	87.7 ^g	84.7 ^g	-
1984-1986 ^b	92.6	93.6	80.4	92.9	94.0	80.6	87.0 ^g	89.4 ^g	-
1987-1989 ^b	95.2	95.0	95.7	95.5	95.4	95.3	88.0 ^g	87.4 ^g	-
1990-1992 ^b	95.8	95.8	93.7	96.2	96.1	94.6	84.2 ^g	89.0 ^g	-
1993-1995 ^b	95.8	96.4	86.7	96.1	96.6	87.8	88.0	89.4	-
1996-1998 ^b	95.6	96.3	86.6	95.8	96.5	86.7	89.0	90.3	-
1999-2001 ^b	96.1	96.4	91.8	96.4	96.7	92.8	87.6	89.1	-
2002-2004 ^b	96.0	96.5	89.9	96.5	97.0	90.9	85.1	84.8 ^g	-
2005-2009 ^b	96.9	97.0	95.7	97.4	97.4	96.4	91.4	91.4	-
2010-2016 ^b	96.8 ^f	97.1 ^f	94.6 ^f	97.0 ^f	97.3 ^f	95.0 ^f	93.1	93.0	89.5 ^g
5-Year Period Survival (Percent) ^{cd}									
2016	95.1	95.9	89.2	95.1	96.0	89.5	93.2	93.9	84.6
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	16,682	14,675	2,007	14,758	12,954	1,804	540	458	82
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	68	68	65	68	68	64	63	61	70
Regional	18	18	19	19	18	19	20	21	15
Distant	12	12	14	12	12	14	14	15	12
Unstaged/Unknown	2	1	3	1	1	3	3	2	4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	95.6	-	-	95.6	-	-	91.9	-	-
Ages 45-54	95.1	-	-	95.2	-	-	90.3	-	-
Ages 55-64	90.1	-	-	89.9	-	-	93.9	-	-
Ages 65-74	84.8	-	-	83.1	-	-	-	-	-
Ages 75+	74.7 ^g	-	-	77.2 ^h	-	-	-	-	-
Ages <65	95.3	-	-	95.3	-	-	92.4	-	-
Ages 65+	82.8	-	-	82.1	-	-	-	-	-
Stage ^e :									
All Stages	95.0	95.6	90.6	95.0	95.7	90.4	92.3	92.5	88.4
Localized	99.0	99.1	98.4	99.0	99.1	98.0	98.8	97.9	97.1
Regional	96.0	96.6	91.3	96.2	96.8	92.0	88.6	89.9	-
Distant	72.5	75.0	57.0	73.0	75.5	57.7	68.9 ^g	71.5 ^g	-
Unstaged/Unknown	81.6	89.0	55.6 ^g	79.3	87.5	55.2 ^h	-	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.⁻ Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 26.8
Cancer of the Thyroid (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	83	75	87	-	-	-
1970-1973 ^a	-	-	-	86	82	87	-	-	-
1975-1977 ^b	92.2	91.0	92.5	91.8	90.6	92.3	89.8	-	91.0
1978-1980 ^b	92.1	87.2	93.6	91.5	87.5	92.7	90.1	68.0 ^h	95.5
1981-1983 ^b	93.6	92.2	93.9	93.1	90.9	93.7	96.4	100.0	93.2
1984-1986 ^b	93.2	89.9	94.3	93.2	89.4	94.4	89.5	86.1 ^g	90.3
1987-1989 ^b	94.4	91.6	95.2	94.1	91.6	95.0	92.3	91.2 ^g	92.3
1990-1992 ^b	94.3	90.5	95.5	94.9	91.6	96.0	85.9	84.5 ^g	86.3
1993-1995 ^b	95.4	91.6	96.7	95.6	91.5	96.9	93.2	87.4 ^g	94.3
1996-1998 ^b	95.6	91.0	96.9	95.9	91.3	97.3	95.1	86.8 ^g	96.5
1999-2001 ^b	96.5	94.2	97.1	96.8	94.8	97.4	92.1	88.4 ^g	92.4
2002-2004 ^b	97.3	93.9	98.3	97.4	94.1	98.3	95.9	93.9	96.0
2005-2009 ^b	98.2	96.4	98.6	98.4	96.8	98.8	97.0	90.2	97.9
2010-2016 ^b	98.6 ^f	96.2 ^f	99.0 ^f	98.8 ^f	96.7 ^f	99.3 ^f	96.7	91.6	97.5 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	98.4	96.2	99.0	98.6	96.4	99.1	97.0	93.4	97.6
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	78,663	18,363	60,300	62,568	15,130	47,438	5,628	971	4,657
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	67	57	69	67	57	70	79	72	81
Regional	28	34	26	28	35	26	14	18	13
Distant	4	6	3	3	6	3	5	7	4
Unstaged/Unknown	2	2	2	2	2	2	2	3	2
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	99.7	99.2	99.8	99.8	99.4	99.8	98.9	95.0	99.5
Ages 45-54	98.9	96.7	99.5	98.9	96.7	99.5	99.0	96.6	99.2
Ages 55-64	97.9	95.3	98.9	98.2	95.2	99.3	95.5	94.2	95.5
Ages 65-74	96.7	93.0	97.7	97.1	93.8	97.9	94.6	82.5 ^g	97.1
Ages 75+	87.3	86.0	87.7	89.5	87.9	89.8	79.6	76.1 ^h	78.4
Ages <65	99.1	97.3	99.6	99.1	97.3	99.7	98.3	95.5	98.8
Ages 65+	94.1	91.0	94.9	94.9	92.2	95.4	90.7	81.8	91.9
Stage ^e :									
All Stages	98.3	95.9	98.9	98.5	96.2	99.1	97.2	92.8	97.9
Localized	99.9	99.8	99.9	99.9	99.8	99.9	99.8	99.3	99.9
Regional	98.3	96.5	99.0	98.4	96.6	99.2	94.8	86.6	97.0
Distant	54.9	51.7	57.2	55.1	51.1	58.3	48.2	40.2 ^g	49.8
Unstaged/Unknown	88.5	80.6	91.0	88.4	82.4	90.5	82.7	70.3 ^h	85.5

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).^c Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.^d Based on follow-up of patients into 2017.^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 27.8
Cancer of the Urinary Bladder (Invasive and *In Situ*)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	53	53	53	24	24	24
1970-1973 ^a	-	-	-	61	61	60	36	38	27
1975-1977 ^b	72.3	73.7	68.3	73.3	74.3	70.3	50.3	56.5	38.1 ^g
1978-1980 ^b	73.9	75.0	70.4	74.7	75.4	72.4	54.7	62.8	40.0
1981-1983 ^b	76.7	78.0	72.8	77.3	78.5	74.1	59.5	64.9	47.0 ^g
1984-1986 ^b	76.6	78.0	72.7	77.2	78.4	73.6	59.4	62.3	52.8
1987-1989 ^b	79.0	81.3	72.0	79.8	82.0	73.2	62.6	67.5	52.9
1990-1992 ^b	79.2	81.7	71.9	80.3	82.6	73.2	63.3	66.0	58.5
1993-1995 ^b	80.2	82.1	75.0	81.1	82.5	76.9	60.7	68.0	46.2
1996-1998 ^b	79.1	80.3	75.4	79.8	81.1	76.0	62.9	65.9	56.0
1999-2001 ^b	80.0	80.9	77.2	81.0	81.5	79.4	67.5	71.8	60.1
2002-2004 ^b	79.9	81.7	74.7	80.9	82.4	76.4	61.7	67.1	52.4
2005-2009 ^b	79.1	80.5	74.9	79.9	81.1	76.1	65.8	70.0	57.6
2010-2016 ^b	78.1 ^f	79.0 ^f	75.3 ^f	79.0 ^f	79.5 ^f	77.0 ^f	64.9 ^f	69.1 ^f	56.8 ^f
5-Year Period Survival (Percent) ^{cd}									
2016	76.9	78.2	72.8	77.3	78.4	73.8	64.1	68.4	56.1
Stage Distribution (%) 2010-2016 ^{ce}									
All Stages									
Number of cases	91,766	69,653	22,113	80,385	61,596	18,789	5,331	3,507	1,824
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
In Situ	51	52	50	52	52	51	40	44	33
Localized	34	34	32	34	34	32	36	36	38
Regional	7	7	8	7	7	8	11	9	13
Distant	5	4	6	5	4	6	9	7	11
Unstaged/Unknown	3	3	3	3	2	3	4	4	4
5-Year Relative Survival (Percent), 2010-2016 ^c									
Age at Diagnosis:									
Ages <45	86.9	88.7	82.4	88.1	89.4	84.8	69.0	73.7	57.4 ^g
Ages 45-54	83.8	84.5	81.6	85.0	85.4	83.8	68.7	72.6	58.8
Ages 55-64	81.2	81.6	80.0	81.9	81.9	82.0	66.8	70.1	58.0
Ages 65-74	80.3	81.1	77.5	80.4	81.1	77.8	67.7	70.3	62.0
Ages 75+	68.9	71.2	62.7	69.5	71.5	63.8	54.6	60.3	47.7
Ages <65	82.3	82.8	80.6	83.1	83.2	82.7	67.5	71.1	58.2
Ages 65+	74.2	76.0	68.7	74.6	76.2	69.5	61.1	65.9	53.4
Stage ^e :									
All Stages	76.9	78.3	72.4	77.3	78.5	73.5	63.9	68.4	55.2
In Situ	95.8	95.5	97.0	95.8	95.4	97.0	92.5	92.1	93.5
Localized	69.2	71.7	61.2	69.4	71.6	61.7	60.4	65.7	50.7
Regional	36.5	38.0	32.8	37.6	39.0	33.5	27.3	26.1	28.0
Distant	5.5	6.2	4.0	5.5	6.1	4.3	3.4	4.8	1.7
Unstaged/Unknown	47.9	52.3	36.6	46.0	49.7	36.2	39.3	46.3 ^g	25.1 ^g

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2017. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2017.

^d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.


^f The difference between 1975-1977 and 2010-2016 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Childhood Cancer 5-Year Observed Survival (%) by ICCC Group^a and Race/Ethnicity Both Sexes, Under 20 Years of Age, 2010-2016



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005; Vol 103, No. 7, pg 1457-1467.

^a Excludes myelodysplastic syndromes (MDS) and benign brain tumors.

^b American Indian/Alaska Native. Survival data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Survival data for Hispanics are based on NHIA and excludes cases from the Alaska Native Registry.